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Abstract 
Sensitive, real-time detection of biomarkers is of critical importance for rapid and accurate 
diagnosis of disease for point-of-care (POC) technologies.  Current methods, while sensitive, do 
not adequately allow for POC applications due to several limitations, including complex 
instrumentation, high reagent consumption, and cost.  We have investigated two novel 
nanoarchitectures, the nanocoax and the nanodendrite, as electrochemical biosensors towards the 
POC detection of infectious disease biomarkers to overcome these limitations.  The nanocoax 
architecture is composed of vertically-oriented, nanoscale coaxial electrodes, with coax cores 
and shields serving as integrated working and counter electrodes, respectively.  The dendritic 
structure consists of metallic nanocrystals extending from the working electrode, increasing 
sensor surface area.   
 
Nanocoaxial- and nanodendritic-based electrochemical sensors were fabricated and developed 
for the detection of bacterial toxins using an electrochemical enzyme-linked immunosorbent 
assay (ELISA) and differential pulse voltammetry (DPV).  Proof-of-concept was demonstrated 
for the detection of cholera toxin (CT).  Both nanoarchitectures exhibited levels of sensitivity 
that are comparable to the standard optical ELISA used widely in clinical applications.  In 
addition to matching the detection profile of the standard ELISA, these electrochemical 
nanosensors provide a simple electrochemical readout and a miniaturized platform with 
multiplexing capabilities toward POC implementation.  Further development as suggested in this 
thesis may lead to increases in sensitivity, enhancing the attractiveness of the architectures for 
future POC devices.        
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Introduction 
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1.1 Point-of-care diagnostics for infectious disease  
Highly specific and sensitive diagnostic tools for clinically relevant disease biomarkers 
are critical in enabling accurate disease detection and monitoring.  In spite of significant 
efforts, there currently remains an unmet need for such diagnostic tools in the form of 
point-of-care (POC) technologies, which would allow for on-site, real-time patient testing 
and diagnosis.  The importance of such POC diagnostic development is highlighted by a 
recent rise in several global epidemics.  Emerging and re-emerging infectious diseases 
constitute some of the most significant public health challenges facing the global 
community.  For example, cholera continues to inflict high rates of mortality in resource 
limited areas1,2, and Ebola outbreaks with extremely high instances of fatality present a 
challenge to even the most sophisticated medical establishments3. In addition, malaria, 
tuberculosis, and HIV constitute the majority of infectious-disease burdens, which 
disproportionately afflict the developing world4.  Due to globalization and international 
travel, there is now an additional increased threat of an accelerated epidemic-to-pandemic 
transition of these communicable diseases5,6.  Therefore, accurate and timely 
confirmation of disease is essential in the implementation of preventative and protective 
public health measures.  Robust POC technologies would facilitate better prevention and 
earlier response, enabling accurate diagnosis and proper subsequent treatment.   
 
Conventional “gold standard” techniques in clinical infectious disease diagnostics include 
enzyme-linked immunosorbent assays (ELISA) and polymerase chain reaction (PCR)7–9  
Briefly, these diagnostic methods detect a target disease biomarker, specifically any 
molecule (e.g. protein, DNA, RNA, whole virus, toxin) whose expression level or 
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presence is indicative of disease state.  The ELISA is the most commonly-used method 
for clinical protein detection for a host of human diseases, including cancer biomarker 
detection and bacterial toxin detection10–12.  However, cost and the need for complex 
optical instrumentation required for an ELISA measurement limit its potential for 
deployment in POC settings.  Microarrays and liquid chromatography-mass spectrometry 
based (LC-MS-based) proteomics provide alternative platforms to ELISA-based 
methods.  While both technologies are highly sensitive and allow for multiplexing, they 
also require complex instrumentation, specialized consumables, and a high skill set for 
users13–16. Recently, PCR has been adapted for infectious disease detection17,18.  While 
PCR is a highly sensitive technique and can differentiate between multiple pathogens, the 
requirement of skilled technicians, risk of contamination, and prolonged analysis times 
prevents its use in POC settings.  
 
The aforementioned diagnostic assays fail to provide critically-needed capabilities 
required for POC technologies, such as real-time, cost-effective detection of infectious 
disease markers, and device portability.  Rapid turnaround time from test to diagnosis 
would allow for on-site treatment of the patient and is crucial in the prevention of disease 
outbreak19. In order to be a viable option in low resource settings, POC devices must be 
low-cost and easily portable to a potentially laboratory-free test site20,21.  As mentioned 
above, many conventional diagnostics require complex instrumentation and sophisticated 
reagents; a portable POC device would not be able to accommodate such equipment.  A 
lack of trained staff as well as poor laboratory infrastructure in these areas emphasize the 
need for a simple, transportable POC device that can be utilized without extensive 
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specialized training22–24.  In addition, a POC platform should allow for facile 
multiplexing for the simultaneous detection of multiple biomarkers.  Many infectious 
diseases exhibit the same symptoms25; multiplexing tests for several diseases in parallel 
on the same device, thereby increasing accurate diagnosis and proper subsequent 
treatment.   
 
Presently, the majority of infectious disease POC diagnostics available for use in resource 
limited settings are microscopy, agglutination tests, and lateral flow assays (LFA)26–28.  
Microscopy provides an economical, specific diagnostic platform for detection of live 
infections when performed with clean equipment and an appropriately trained staff29,30.  
However, procurement of quality slides and microscopes presents a major challenge, and 
many rural facilities suffer from staffing constraints and untrained personnel.  
Agglutination tests provide a simple visual readout by eye based on the aggregation of 
latex beads in the presence of a specific pathogen (Fig 1.1.1a)31–33.  Presently, 
agglutination tests for infectious diseases are utilized primarily for the detection of 
HIV34,35, as well as several other sexually transmitted infections such as hepatitis C virus 
(HCV) and syphilis36.  Although cost-effective, agglutination assays are only semi-
quantitative at best and the reagents have a limited shelf-life in non-refrigerated POC 
settings.  LFAs (commonly termed “dipsticks”) are the most successful POC diagnostic 
format commercially available, providing the platform for the at-home pregnancy test.  
LFAs are also currently used for POC detection of infectious diseases such as malaria37,38 
and HIV39,40. Detection is based on visual readout; a colored strip appears when a 
sufficient quantity of the analyte of interest is present in the sample tested (Fig 1.1.1b)41–
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43.  LFAs for POC detection of infectious disease are relatively inexpensive and require 
low sample volume.  In addition, LFAs provide a quicker turnaround time (~15 min) and 
are often more sensitive than their agglutination assay counterpart44,45.  However, similar 
to agglutination tests, LFAs are not quantitative and reagent stability under harsh 
conditions remains a challenge46,47.  Moreover, while a major advantage of agglutination 
tests and LFAs is ease of portability, both assays tend not to meet the sensitivity and 
specificity criteria required for rapid test approval in most developed countries (>99% 
sensitivity and ≥98% specificity)48.  Agglutination tests and LFAs may be adequate for 
certain “present/not present”-type diagnostic purposes, however further improvement of 
these devices and new innovative approaches must be taken to develop sensitive and 
quantitative POC detection systems for infectious disease.  
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Figure 1.1.1. Current infectious disease POC diagnostics.  (a) Agglutination assays 
consist of beads with capture antibodies that, when mixed with sample containing the 
target analyte, result in bead aggregation.  A positive result (+) produces aggregation that 
is discernible by eye from the colloidal solution (-) where the analyte is absent.  Images 
adapted from reference4949 and reference5050. (b) Typical LFA format. Sample is applied 
to the end of the dipstick; target analyte present in the sample binds to the antibody-
conjugated label. Analyte-antibody complexes bind to the test line to return a positive 
result (+) of two red strips (test line and control line). If the analyte is absent, the label 
binds to the control line only, generating a negative result (-) of one red strip.  Images 
adapted from reference5151.       
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One step to improve current POC technologies is the integration of microfluidics onto 
these existing detection platforms.  Microfluidics utilizes microfabricated channels, 
commonly composed of elastomers such as polydimethylsiloxane (PDMS), to enclose 
and manipulate small volumes of fluid, allowing for lab-on-chip devices (i.e. micrototal 
analysis systems)52–54.  A critical application of lab-on-chip devices is the automation of 
sample preparation, enabling steps such as purification, mixing, and extraction without 
any user interference (Figure 1.1.2)55,56.  Sample preparation in low resource settings 
poses a difficult task due to staffing constraints and limited reagent shelf life in harsh 
conditions; integration of microfluidics to produce a lab-on-chip device could greatly 
reduce the need for trained staff, and improve reagent lifetime via enclosed, on-chip 
reagent storage.  In addition, microfluidic platforms composed of polymers such as 
PDMS are manufacturable by methods that allow high production at very low cost-per-
part57.  Therefore, incorporation of microfluidics onto POC platforms could greatly 
advance diagnostics in resource limited areas, while feasibly allowing these lab-on-chip 
devices to be cost-effective. 
 
 
Figure 1.1.2. Example of a microfluidic device composed of PDMS for automated 
sample preparation.  Image adapted from reference5858. 
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A multitude of current POC diagnostic platforms have been integrated with microfluidics 
in an attempt towards developing prospective next-generation POC devices58–60.  Several 
LFA-based platforms have been integrated with microfluidics61–64. A major pitfall of 
LFAs is the lack of flow rate control which results in non-uniform dispersion and mixing 
of sample over the strip and as a consequence, variability in batch-to-batch 
reproducibility.  The addition of microfluidics allows for controlled sample delivery and 
reagent mixing, thereby generating more reproducible and more quantitative results65,66.  
However, many of these adapted assays require external bulky bench-top pumps or 
involve microfluidics that are too complex to be cost-effective58.  Despite improving 
sensitivity, the added complexity of these LFA-based platforms takes away from desired 
POC qualities.      
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1.2 Nanoscale-based detection platforms  
Over the past few decades, nanotechnology has emerged as a rapidly growing, inter-
disciplinary field with high expectations to lead to major advancements in the 
development of biosensors.  Briefly, the field of nanotechnology involves the study, 
fabrication, and use of structures with dimensions typically smaller than 1 µm.  At the 
sub-micron scale, materials exhibit unique optical, electrical, and structural behaviors that 
significantly differ from their bulk, macroscopic properties67–69.    One such effect is seen 
optically with nanoparticles, which can emit different frequencies of visible light based 
on their size.  For example, bulk gold exhibits the ‘golden’ yellow color with which we 
are familiar; however, gold nanoparticles can appear anywhere from red to blue 
depending on their size (Fig 1.2.1a)70.  Similarly, quantum dots (QDs) are semiconductor 
nanoparticles whose fluorescence emission wavelength is size dependent (Fig 1.2.1b).  
These color-tunable particles provide a sharp, detailed spectrum and do not exhibit 
photobleaching, unlike commonly used organic fluorescent dyes71.  In addition, 
nanoscaled dimensions exhibit unique structural and electrical properties due to an 
increased surface area to volume ratio.  This places a majority of the atoms at the 
structure surface, allowing atoms to be more readily accessible for chemical reactions, 
biofunctionalization, and signal detection72.             
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Figure 1.2.1. Nanoscale materials and their properties.  Size-dependent spectrum of (a) 
gold nanoparticles and (b) CdSe semiconductor quantum dots.  (c)  Structure of a single-
walled carbon nanotube (SWCNT) which is composed solely of surface atoms.  Image 
credit (a) reference7373 (b) reference7474 (c) reference7575.   
 
The unique properties of nanoscale materials - such as nanotubes76, nanowires77,78 and 
nanoparticles79– have been manipulated for the development of sensitive biosensors.  
Carbon nanotubes (CNTs) are an exemplary, well-studied nanomaterial whose structure 
resembles a cylindrical graphene sheet (Fig 1.2.1c)80–83.  The unique structure of CNTs 
consists exclusively of surface atoms; thus, small changes in the surrounding 
environment can cause drastic changes in their electrical and optical properties.  In 
addition, their diameters are comparable to the size of single molecules (~1-3 nm), 
making CNTs very sensitive to the adsorption or binding of biomolecules.  In this 
fashion, CNTs can function as sensitive, label-free biosensors upon binding of a target 
molecule84–86.  For example, a CNT-based immunosensor demonstrated detection of 
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disease-specific autoantibodies from human serum, with sensitivity and specificity that 
was significantly greater than established ELISA and microarray methods87.  In the same 
manner, silicon nanowires have been used for ultrasensitive biomolecule detection.  
Patolsky et al. demonstrated selective, electrical detection of a single virus molecule 
using a silicon nanowire field effect transistor, exhibiting the extraordinary potential of 
nanotechnology to detect viral threats at the single molecule level88.   
 
Nanoparticles have also received much attention in their wide variety of applications 
towards advancing biosensor technology89,90.  Nanoparticles can be biocompatible and 
exhibit high surface area, enabling biomolecule immobilization and subsequent signal 
amplification.  In this manner, nanoparticles have been labeled with reporter molecules 
(e.g. enzyme, redox species) to enhance signal and increase detection sensitivity91.  Liu et 
al. demonstrated highly sensitive protein detection using enzyme-labeled gold 
nanoparticles92.  Labeled gold nanoparticles detected the cancer biomarker 
carcinoembryonic antigen (CEA) with a 130-fold increase in sensitivity over the 
conventional ELISA, with a detection limit of 12 ng/L.   
 
Nanotechnology research has predominately focused on biomedical applications, 
specifically on advancing drug delivery, therapeutics, and imaging in oncologic disease93–
96.  Due to the inability of most drugs to efficiently reach the target tissue, much effort 
has been put into improving drug delivery.  Because of their small size, nanoparticles 
loaded with drug can penetrate through small capillaries and several biological barriers 
(such as the blood brain barrier), which allows for efficient drug accumulation at the 
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target site97,98.  In addition, drugs used for chemotherapy indiscriminately damage 
malignant and normal cells, resulting in the adverse side effects associated with 
treatment.  Targeted drug delivery to the cancer cells utilizing labeled nanoparticles 
would selectively target the tumor cells and lessen the negative side effects of 
chemotherapy99.  Furthermore, magnetic nanoparticles can be delivered to the tumor site 
and allow for improved, site-directed thermal ablation therapeutics in the removal of 
malignant cells100,101.  Nanoparticles are also being exploited to improve tumor imaging 
where current techniques face the disadvantage of fluorescence photobleaching; QDs are 
resistant to photobleaching and, like other nanoparticles, can be labeled to directly target 
the site of interest for imaging102.   
 
Although much of the aforementioned research has primarily focused on oncologic 
disease applications in a clinical setting, significant attention has shifted towards 
infectious disease applications due to a recent rise in antibiotic resistance paralleled with 
globalization7,103,104.  The need for sensitive and robust diagnostics to monitor and detect 
infectious disease has become essential as the threat of a pandemic has become 
increasingly real. Several studies have been performed on improving LFAs and 
agglutination tests with the addition of nanomaterials105,106. LFAs for malaria107 and 
HIV108 detection have been improved using gold nanoparticles as the contrast agent.  
Gold nanoparticles have a high affinity for biomolecule labeling and remain stable in 
colloidal solution for long periods of time, producing more sensitive LFAs compared to 
the traditional dyed-latex counterpart109.  Gold nanoparticles have also been adapted to 
improve agglutination assays110,111.  The inertness and stability of colloidal gold 
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decreases innate particle aggregation seen with latex beads, allowing for true signal to be 
easily discernable from background aggregation and thereby increasing sensitivity112.  In 
addition, the incorporation of nanoparticles has allowed for quantification due to the 
occurrence of plasmon coupling in aggregated metallic nanoparticles.  For example, 
Halas et al. detected immunoglobulin from whole blood with a sensitivity range 
comparable to the standard ELISA113.  However in order to make the assay quantitative, a 
spectrophotometer was required, introducing complex instrumentation that may not be 
amenable for POC applications.  Interfacing nanomaterials with previous POC platforms 
improves the performance and stability of these existing technologies; however in order 
to fully realize a truly POC diagnostic for infectious diseases, multiplexed devices must 
be developed.    
 
The ability to simultaneously screen for multiple pathogens would provide a critical tool 
in preventing outbreaks and disease spread.  Many diseases share similar symptoms and 
so diagnosis may be near impossible without a panel of disease markers with which to 
screen against114.  In addition, pathogens such as the Plasmodium parasites and HIV are 
present in multiple strains, and correct strain identification could improve the efficiency 
of treatment115,116.  Therefore, major focus has been placed on the development of 
multiplexed assay systems that can detect a host of infectious disease biomarkers (e.g. 
molecules, whole viruses, bacteria) simultaneously.  Quantum dot barcode assays are one 
approach that has been well developed as a nanotechnology-based multiplexed assay117–
119.  In such an assay, QDs of a unique color are labeled respectively to a specific target 
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biomarker of interest; therefore, multiple targets can be probed for simultaneously, with 
each target corresponding to its own unique color, or “barcode” (Figure 1.2.2).   
 
Multiplexed barcode assays have been developed for infectious diseases such as HIV, 
malaria, syphilis, HCV, and hepatitis B virus (HBV)120–122. These barcode assays rapidly 
detected multiple infectious pathogens simultaneously from low sample volumes (~100 
µl) and demonstrated sensitivities that exceeded the standard ELISA detection method.  
For example, Klostranec et al. observed a 50-fold improvement in the multiplexed 
detection of HIV, HBV, and HCV compared to FDA-approved ELISA kits120.  However, 
these assays require considerable laboratory equipment (e.g. spectrophotometers) in order 
to detect and quantify barcode signal, proving it difficult to adapt these assays to POC 
applications.  Recently, a quantum dot barcode assay was integrated with a handheld 
smartphone optical device123, demonstrating rapid, multiplexed detection of HIV and 
hepatitis from real patient samples.  While this handheld device holds potential for 
portability of a barcode assay, the sensitivity was lacking (1000 viral copies/ml) 
compared to standard PCR diagnostics, whose detection limits can reach as low as 40 
viral copies/ml124.   Further development in the sensitivity and portability of such 
handheld devices must be explored before optical readout assays could be considered for 
POC diagnostics.  
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Figure 1.2.2. Barcode assay schematic.  (a) Sample is added to solution containing 
labeled QDs of varying fluorescent color.  Each unique QD color, or “barcode”, is 
labeled with antibody against a specific target biomarker.  In this case, green fluorescing 
QDs are labeled with anti-HIV Ab, red fluorescing QDs are labeled with anti-HBV Ab, 
and blue-fluorescing QDs are labeled with anti-HCV Ab.  After incubation with sample, 
a capture assay is performed to isolate only QDs that have target analyte bound to them.  
(b) Presence of target analyte is observed with fluorescence imaging of captured QDs.  
(c) Signal intensity is determined for each QD barcode in order to quantify analyte.    
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1.3 Electrochemical sensors for point-of-care platforms  
In the studies previously described (e.g. LFAs, agglutination, barcode assays), the 
majority of the POC platforms is based on optical readout.  While optical detection 
methods have proven sensitive and reliable in clinical settings, the need for expensive and 
bulky instrumentation inhibits their use for POC needs.  Electrochemical detection offers 
several advantages over optical methods for such POC applications125–130.  Platforms for 
electrochemical detection are easily amenable to miniaturization, allowing for facile 
multiplexing and integration with microfluidic systems.  Optical systems are often still 
too difficult to miniaturize while maintaining sensitivity, and therefore require larger 
reagent volumes and longer analysis time.  In addition, electrochemical techniques do not 
require the optical instrumentation (Fig 1.3.1a) that impedes the portability of optical 
readout devices.  Instead, electrochemical signals are measured by a potentiostat.  
Potentiostats operate by controlling voltage to a constant value and recording change in 
current due to an electrochemical event131.  Miniaturized handheld potentiostats are 
commercially available (Fig 1.3.1b) and allow for portability of electrochemical devices, 
an essential POC factor that restricts many technologies from becoming POC.  
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Figure 1.3.1. Instrumentation required for optical and electrochemical readout.  (a) For 
optical detection, a standard spectrophotometer is used to measure a 96-well plate for 
conventional ELISA reactions. Image taken from reference132132.  (b)  Handheld 
potentiostats are used for portable, sensitive electrochemical detection, an option not 
readily available for the pictured spectrophotometer.  Image adapted from 
reference133133.   
 
Electrochemical detection offers the ability to achieve sensitive and specific detection of 
biomarkers at low cost and in real-time, utilizing simple instrumentation134–136.  The 
development and commercial success of electrochemical glucose sensor strips for blood 
sugar monitoring in diabetic patients demonstrates the low-cost and portability of such an 
electrochemical-based POC technology137.  However as mentioned, many POC 
technologies have predominately been based on optical readout.  Previously, 
electrochemical sensors suffered from a lack of electrode surface architectures that would 
allow for high sensitivity comparable to optical methods138,139.  Additionally, while the 
success of the glucose sensor is compelling for electrochemical POC devices, the 
detection scheme is based on an inherent redox reaction linked to the oxidation of glucose 
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by glucose oxidase (Figure 1.3.2)140.  Therefore, detection of other analytes (e.g. non-
redox active molecules) would require further development of electrochemical-based 
detection strategies.    
 
 
Figure 1.3.2. Basic mechanism of glucose sensor detection scheme. Image taken from 
reference 141141.   
 
Focus has shifted to electrochemical means in the past decade with the explosion of 
nanotechnology coinciding with the development of numerous electrochemical-based 
detection strategies.    With this rapid growth of nanotechnology, there has been a surge 
of novel nanoarchitectures that, by shrinking sensor dimensions and thereby enhancing  
electrode surface area, have increased electrochemical signal-to-noise ratios compared to 
their macroscopic counterparts142–144.  The high surface areas of these electrodes 
significantly improve sensitivity, placing electrochemical methods on a competitive level 
with optical technologies.  Furthermore, countless electrochemical detection strategies 
have been developed to monitor analytes with high sensitivity that are not inherently 
redox active, including proteins145,146, DNA147,148, microRNAs149, metabolites150,151, 
drugs152, and enzymatic activity153.  Several well-established approaches include 
sandwich-type assays to deliver electrochemically active groups154–156, electrochemically 
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adapted barcode assays157,158, and non-covalent redox reporter systems159,160.  Moreover, 
using these electrochemical detection strategies in conjunction with nanostructured 
electrode surfaces – such as carbon nanotubes 161, nanowires162, and metallic 
nanoparticles163– exhibit increased sensitivity for biomarker detection over conventional 
techniques.  For example, Zhang et al. achieved femtomolar detection levels of DNA 
using a nanoparticle-based platform combined with a non-covalent redox reporter 
system164.  In addition, the assay exhibited excellent selectivity against base pair 
mismatch and a rapid analysis time, two components lacking in the standard PCR 
technique.    
 
Many of these developed electrochemical strategies employed in conjunction with 
nanostructures have been characterized for the detection of oncologic disease165,166.  The 
development of highly sensitive, cost-effective detection and monitoring strategies of 
cancer biomarkers is critical due to the disease’s prevalence and high rate of mortality at 
late stage diagnosis. Ultrasensitive detection of cancer biomarkers with electrochemical-
based platforms has been achieved, reaching attomolar detection limits for multiple 
biomarker types, including protein167, DNA168, and microRNA169.  For example, Tang et 
al. developed an ultrasensitive immunosensor for the detection of cancer biomarker 
interleukin-6 (IL-6) using an electrochemical enzyme-labeled sandwich assay (Figure 
1.3.3)170.  The detection limit was remarkably low at 10 fg/ml (~390 aM) with a dynamic 
range extending to 1300 fg/ml.  Many cancer biomarkers have threshold levels (i.e. 
concentrations correlating to disease state) in the pg/ml range; therefore these ultralow 
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detection limits demonstrated with electrochemical platforms could facilitate early 
detection and proper monitoring of disease progression171–173. 
 
 
Figure 1.3.3. Detection of cancer biomarker via electrochemical sandwich assay.  (a) 
Device composed of 8 individually addressable electrodes, each with 0.45 mm2 area.  (b) 
Schematic of electrochemical sandwich assay to detect cancer biomarker IL-6, using 
horse radish peroxidase (HRP) as the amplification tag.  (c)  Amperometric response after 
exposure to diluted serum containing IL-6 and HRP-labeled secondary antibody (left); 
dynamic range of sensor for IL-6 detection (right).   [Image from reference 170] 
 
Impressively, nano-based electrochemical techniques allow some of these detection 
methods to be label-free, achieving sensitive and specific detection of cancer biomarkers 
without signal enhancement via an enzyme or redox reporter system174–176.  As previously 
mentioned, nanostructured electrodes (notably CNTs and nanowires) are very sensitive to 
the adsorption or binding of biomolecules due to the size comparability of a single 
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molecule to the nanostructured aspect of the electrode.  For example, Lieber et al. 
demonstrated sensitive label-free, multiplexed electrical detection of cancer biomarkers 
from serum utilizing a silicon nanowire sensor array (Figure 1.3.4)177.  They achieved a 
detection limit of 0.9 pg/ml prostate-specific antigen (PSA), surpassing the detection 
limit of the conventional ELISA (3 pg/ml).  Additionally, carbon nanotube based 
platforms are easily amenable for label-free electrochemical detection, as demonstrated 
by Tran et al.  Their CNT-based immunosensor detected the prostate cancer microRNA 
biomarker miR-141 with a very low detection limit of 8 fM, significantly below the 
typical sub-pM threshold level of many microRNA biomarkers178. 
 
 
Figure 1.3.4. Detection of cancer biomarkers with nanowire arrays.  (a) Arrays were 
fabricated with ~200 individually addressable nanowires.  Top image: full nanowire 
array, 8 mm x 1.2 mm in size.  Bottom image: view inside the red rectangle; black lines 
denote individual silicon nanowires.  (b) Top: schematic of nanowires conjugated with 
anti-PSA antibody. Below: detection and sensitivity range for nanowire capture of PSA 
denoted by conductance change vs. log scale of PSA concentration.    Image from 
reference 177. 
22 
 
While these electrochemical-based nanosensors offer highly sensitive tools for potential 
oncologic disease monitoring and diagnosis, there remain several challenges for 
continued development towards POC biosensors.  A predominant issue is the lack of 
clinically validated cancer biomarkers; only nine cancer biomarkers are currently FDA-
approved despite an extensive list of candidate biomarkers179.  The low numbers of 
validated biomarkers (~3% of all candidate biomarkers) is largely attributed to the 
inability of current technologies to identify biomarkers with high specificity for a 
particular disease180.  Even the nine clinically approved biomarkers are neither specific 
nor sensitive enough to diagnose the correct disease on their own.  Therefore, biomarker 
discovery and clinical verification must continue in order to develop multiplexed panels 
of validated biomarkers for sensitive and specific disease diagnosis181,182.  In addition, a 
significant challenge for a majority of electrochemical biomarker sensors is biofouling 
and contamination of the electrode surface with complex biological samples such as 
whole serum183; this prevents clinical validation of the sensors with real sample testing.  
The integration of microfluidics onto these electrochemical-based platforms could greatly 
advance these tools for clinical diagnostics by integrating sample pre-treatment (e.g. 
extraction, purification, mixing) of complex biological materials184–186.  However, the 
addition of complex microfluidics negates the cost-effectiveness of electrochemical 
platforms; therefore there remains a need to affordably integrate microfluidics onto these 
systems.   
 
While emphasis has previously been placed on electrochemical strategies for oncologic 
disease, electrochemical-based platforms for infectious disease detection remain an 
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unchartered territory in comparison.  However, focus and funding has recently shifted to 
infectious disease applications due to a rapid rise in antibiotic resistance alongside 
growing threats of an epidemic-to-pandemic potential.  Electrochemical sensing schemes 
are being adapted and developed for the detection of infectious disease biomarkers; 
sensitive and specific detection of infectious diseases such as HBV187,188, HCV189,190, 
HIV191–193, and influenza viruses194,195 have been demonstrated utilizing viral nucleic 
acids or viral peptides as the targeted biomarkers.  For example, Chen et al. exhibited 
ultrasensitive electrochemical detection of HIV DNA from complex biological samples.  
Viral DNA was captured onto the electrode surface by complementary probe DNA and 
subsequently detected by a non-covalent redox reporter system, with a detection limit of 
5 aM196.  Although the use of electrochemical sensors towards infectious disease is still 
novel and limited at this time, further development of these technologies will provide an 
attractive option for robust, sensitive POC devices.          
 
Electrochemical nanosensors provide a potential means for sensitive, specific, cost-
effective detection of infectious disease biomarkers with rapid analysis times.  They 
provide a miniaturized platform amenable to multiplexing for the detection of multiple 
infectious disease markers on one device, while maintaining portability and ease of 
deployment in resource limited areas.  With the integration of microfluidics and the hand 
held potentiostat, electrochemical-based sensors present an optimal means of detection in 
the development of infectious disease POC diagnostics.  While their application in 
infectious disease POC is limited at this time, electrochemical-based sensors present an 
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untapped resource to exponentially advance diagnostics in resource limited areas and fill 
the void in infectious disease detection.       
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1.4 Aims of study 
The research presented in this dissertation involves the evaluation of two novel 
nanoarchitectures as electrochemical sensors and their development into biosensors for 
infectious disease detection.  This work was completed in collaboration with the physics 
laboratory of Dr. Michael J. Naughton, where the nanostructures were designed and 
fabricated.   
 
Two nanostructures, the nanocoax and dendrites, were each developed and characterized 
as electrochemical sensors for the detection of cholera toxin (CT).  Fabrication of each 
structure was first investigated and optimized; the structures were then evaluated on their 
electrochemical performance and compared to the standard method of biomarker 
detection (the optical ELISA) using CT as the target biomarker.  Alkaline phosphatase 
titrations and electrochemical ELISAs were the two main determinants of 
electrochemical performance.  CT was used as the benchmark biomarker due to its 
clinical relevance in infectious disease, however the electrochemical ELISA is universal 
and can be utilized for other infectious disease biomarkers whose antibodies are 
commercially available.    
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2.1 Chemicals and reagents 
Cholera toxin subunit B (CT), ferrocenecarboxylic acid (FCA), ethanol, and 
ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma-Aldrich (St. Louis, 
MO). Anti-cholera toxin subunit B antibodies (Abs) and alkaline phosphatase (ALP) 
conjugated Ab were obtained from Abnova (Taipei, Taiwan).  The BluePhos phosphatase 
substrate system was purchased from KPL (Gaithersburg, MD) and p-
aminophenylphosphate (pAPP) was acquired from Gold Biotechnology, Inc. (St. Louis, 
MO).  Hydrogen tetrachloroaurate(III) trihydrate (HAuCl4), sodium dodecyl sulphate 
(SDS), acetic acid (99%), bovine serum albumin (BSA), Tween-20, phosphate buffered 
saline (PBS), and Tris base were obtained from Fisher Scientific (Pittsburgh, PA).  
 
Shipley 1813 photoresist, MF-319 developer, LOR-2A resist, hexamethyldisilazane 
(HDMS), Microposit 1165, and SU-8 were procured from MicroChem Corp. 
(Westborough, MA) and Transetch-N was obtained from Transene Company, Inc. 
(Danvers, MA).  Hydrogen peroxide (27%), ammonium hydroxide (28%), 1H,1H,2H,2H-
perfluorodecyltrichlorosilane (FDTS) (96%) and n-heptane (99%) were purchased from 
Alfa Aesar (Ward Hill, MA).  Polydimethylsiloxane (PDMS) Sylgard 184 silicone 
elastomer kit was purchased from Dow Corning (Midland, MI).  Acetone (99.5%) and 
sulfuric acid (96%) were purchased from J.T. Baker.  EponTM resin 828 and Epikure 3140 
curing agent was provided by Miller-Stephenson Chemical Co. Inc. (Danbury, CT).   
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2.2 Fabrication of nanocoaxial arrays 
Fabrication of nanocoaxial arrays used was generously completed by colleague Dr. Binod 
Rizal in collaboration with the laboratory of Dr. Michael J. Naughton.   
 
2.2.1 Nanoimprint lithography 
Silicon nanopillar (SiNP) arrays were previously prepared to be used as imprint masters 
(Rizal et al., 2013).  The SiNP arrays consisted of pillars with 2 µm height and 200 nm in 
diameter in a hexagonal close-packed array of 1.3 µm periodicity/pitch.  Pillars were 
contained within an array area of 10 × 20 mm2, with a density of ~106 pillars/mm2.  To 
aid in imprinting, a release coating was applied to the SiNP master arrays; the SiNP 
arrays were immersed in a solution consisting of FDTS and n-heptane in the ratio of 
1:1000 (v/v), and then subsequently transferred to acetone for 5 min.  Finally, the master 
arrays were baked at 110°C for 5 min on a hot plate.   
 
Molds were made from a master array with polydimethylsiloxane (PDMS) which was 
mixed in the ratio of 10:1 (w/w) with its curing agent and degassed in a bell-jar desiccator 
connected to a vacuum pump for 30 min.  The PDMS was then poured onto the SiNP 
master array, cured at room temperature for 12 h, and baked for 1 h at 90°C.  The PDMS 
mold was peeled off of the master, and treated with the same release coating as described 
above prior to imprinting. 
 
A thin film of SU-8 2002 was spin-coated on a piranha-cleaned Si wafer at 500 rpm with 
an acceleration of 110 rpm/s for 6 s, followed by 3000 rpm at 550 rpm/s for 36 s.  To 
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remove any residual solvent, the substrate was baked at 65°C for 1 min and then 95°C for 
at 3 min.  The film was cooled to room temperature and then the PDMS mold was placed 
on top of it.  To ensure conformal contact between the mold and the film, a pressure of 
~105 Pa was applied between the SU-8 film and PDMS mold using an in-house 
constructed clamping apparatus.  The PDMS mold and SU-8 were held in contact for 5 
min at 95°C and then exposed to UV light in a mask aligner (MA6, Karl Suss, Denmark) 
at 12 mW/cm2 for 90 s.  A post-exposure bake for 5 min at 95°C was then completed.   
The sample was allowed to cool to room temperature and then the PDMS mold was 
peeled off, releasing the SU-8 nanopillar array which will form the base starting substrate 
in the fabrication of the nanocoax.   
 
2.2.2 Fabrication of hollow cavity nanocoax arrays 
A thin film of Au (~125 nm) was deposited onto the SU-8 nanopillar array via sputter 
deposition (AJA International, Scituate, MA) with 250 W DC power and 0.75 nm/s 
deposition rate.  Atomic layer deposition (Savannah S100, Cambridge Nanotech, 
Waltham, MA) was then used to deposit ~200 nm Al2O3 at 200°C, followed by a sputter 
deposition of Cr (~150 nm) with 200 W DC power and 0.1 nm/s deposition rate.  A layer 
of SU-8 was spin-coated on top of the coaxial array to provide mechanical support and 
was cured by UV exposure (12 mW/cm2; 90 s), followed by a hard bake at 200°C for 1 h.  
A mechanical polisher (Vibromet 2, Buehler) was used to remove the top part of the outer 
Cr of the coax array using an alumina slurry for 2.5 h.  This mechanical decapitation of 
the coax exposed the Al2O3 in the coaxes’ annuli; the annuli cavities were selectively 
etched at room temperature with Transetch-N to a time-controlled depth of approximately 
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500 nm, at a rate of ~20 nm/h.  Nanocoaxial arrays were contained within an area of 1.8 
mm2, with a density of ~106 pillars/mm2.   
 
2.3 Fabrication of dendrites 
2.3.1 Preparation of 2D and 3D substrates 
Planar silicon wafers (University Wafers, Boston, MA) were sonicated in acetone for 5 
min in preparation for metal deposition.  A thin adhesion layer of Ti (~10 nm) was 
deposited onto the Si via sputter deposition, followed by ~125 nm of Au.  The planar Au 
substrates were cut by hand with a diamond scribe into ~ 2x2 cm2 sized samples.     
Si wafers containing pillar arrays were pre-diced into 30 x 16 mm2 substrates using a 
DAD3220 dicing saw (Disco, USA).  Each of these areas contained a 10 x 20 mm2 Si 
pillar array.  These Si pillar substrates were subject to the same metal deposition steps as 
described above for the planar substrates.     
 
2.3.2 Photolithographically-patterned substrates  
Substrates were photolithographically-patterned in order to fabricate uniform and 
electrically-isolated regions for dendritic growth.  Si wafers containing pillar arrays were 
diced into the same dimensions as described above in Section 2.3.1.  The substrates were 
cleaned with 5 min sonication in acetone, rinsed with isopropanol (IPA) and with dH2O, 
and then baked at 200°C for 5 min.  HDMS was spin-coated on the substrate at 3000 rpm 
for 45 s, followed by LOR-2A at the same parameters.  The substrate was then baked at 
150°C for 7 min.  The photoresist Shipley 1813 was spin-coated onto the substrate at a 
ramp of 500 rpm for 5 s, followed by a spin of 4000 rpm for 45 s.  The substrate was 
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baked for 1 min at 105°C then allowed to cool to room temperature.  The substrate was 
then held in contact with a mask and exposed to UV light in the mask aligner for 6.5 s.  
After exposure, the substrate was developed for 90 s in MF-319, rinsed with dH2O for 1 
min, and nitrogen dried. 
 
A thin adhesion layer of ~10 nm Ti was deposited via sputter deposition, immediately 
followed by ~110 nm Au.  To lift-off photoresist, the substrate was immersed in 
Microposit 1165 remover at 60°C overnight, followed by 5 s sonication.  The substrate 
was then sonicated in acetone for 5 min, rinsed with IPA and nitrogen dried.       
In order to protect the address lines, a second round of photolithography was performed 
as described above, except the LOR-2A step was excluded.  UV exposure was performed 
with the same parameters; a second mask was used that exposed only the circular regions 
and the electrode pads.  Substrate patterning was completed after developing with MF-
319 (image of completed substrate shown below). 
 
 
Figure 2.3.1. Completed photolithographically-patterned chip for dendritic growth.  
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2.3.3 Directed electrochemical nanowire assembly 
Directed electrochemical nanowire assembly (DENA) was carried out with a waveform 
generator (Agilent 33600A Series, Santa Clara, CA) using a two-electrode system.  
Waveform was monitored by an oscilloscope (Agilent MSO-X 3024A) during 
electrochemical deposition.  The Au substrate onto which dendritic growth was desired 
served as the working electrode.  A coiled Pt wire or a planar Au chip served as the 
counter electrode.  A square waveform was run with a frequency of 30 MHz, an 
amplitude of 5 Vpp, an offset of -1.25 Vo, a phase of 0, and a duty cycle of 50% in the 
presence of 30 mM HAuCl4.  The growth time was varied.   
 
2.4 Characterization of nanostructures  
2.4.1 Scanning electron microscopy   
Structural integrity of all fabricated nanostructures was confirmed via scanning electron 
microscopy (SEM).  SEM images of the nanocoaxial arrays, and intermittent steps during 
fabrication, were taken using a JEOL JSM-7001F SEM.  Focused ion beam (FIB) milling 
to obtain cross-sectional profile images of the coax was carried out using a JEOL JIB-
4500 FIB with the assistance of Dr. Gregory McMahon.   SEM images of dendritic 
structures were taken using a JEOL JCM-6000 NeoScope benchtop SEM.   
 
2.4.2 Resistance measurements  
Electrical integrity of nanocoaxial arrays was confirmed using a 610B Electrometer 
(Kiethley Instruments, Cleveland, OH) to measure resistance between the working 
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electrode and the counter electrode of each array.  For quality control, only devices with a 
resistance  > 106 Ω were used, as devices with lower resistances were subject to shorting.   
 
2.4.3 Ferrocenecarboxylic acid redox assay  
To confirm electrochemical sensing capabilities of each device, all nanostructures were 
tested with the redox species FCA.  Differential pulse voltammetry (DPV) was performed 
in the presence of 1 mM FCA in PBS, pH 7.4 with the potential range of 0 V to 0.5 V, a 
potential step of 2 mV, a pulse amplitude of 50 mV, a pulse width of 50 ms, a pulse 
sample period of 100 ms, and an equilibrium time of 10 s. 
 
2.4.4 ALP titrations  
Dose titrations of ALP were electrochemically measured on each nanostructure for proof-
of-concept as an electrochemical sensor.  Serial dilutions of ALP in TBS (50 mM Tris, 1 
mM MgCl2, pH 9.0)  were incubated with 1 mM of the enzymatic substrate pAPP in TBS 
for 30 min at room temperature in the dark.  The reaction was stopped with 40 µl of 50 
mM EDTA in TBS.  Approximately 100 µl of each dilution was subsequently pipetted 
onto the nanostructure array for electrochemical measurements.  ALP activity was 
analyzed via DPV; measurements were performed using a potential range of -0.5 V to 0.4 
V, a potential step of 2 mV, a pulse amplitude of 50 mV, a pulse width of 50 ms, a pulse 
sample period of 100 ms, and an equilibrium time of 10 s.  
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2.5 Electrochemical analysis 
2.5.1 Well attachment 
Wells were attached to all substrates prior to electrochemical sensing (to contain solution 
during electrochemical analysis) using one of two epoxy systems: SU-8 3025 photoresist 
or the EponTM resin 828/Epikure 3140 two-part epoxy system.  The choice of epoxy 
system was solely based on reagent availability; both systems were equally durable and 
chemically stable for our purposes.  Wells were fabricated from the base of pipette tips 
(Eppendorf, USA); pipette tips were decapitated with a razor blade to give a well height 
of approximately 1.5 cm.  The base of the tip (i.e. non-severed end) was then attached to 
the substrate, giving a known and uniform well base area of 12.56 mm2 (tip base inner 
diameter = 4 mm).     
 
Prior to well attachment, substrates were either chemically treated with the standard RCA 
clean or were cleaned with UV/ozone, depending on substrate type.  Substrates that were 
coated solely in metal (e.g. Au planar or Au pillar substrates) were RCA cleaned.  
Substrates containing a photoresist coating (e.g. nanocoaxial arrays, 
photolithographically patterned chips for dendrites) were treated with UV/ozone, as RCA 
clean removed the photoresist.  For RCA clean, a 1:1:5 mixture of ammonium hydroxide 
(28%), hydrogen peroxide (27%), and dH2O were heated to 80°C.  Substrates were 
submerged for 10 min, then immediately placed into a beaker of dH2O and rinsed three 
times.  Substrates were then rinsed with 200 proof ethanol and air dried.  Substrates that 
were cleaned with UV/ozone were treated for 20 min with a UV/Ozone ProCleaner Plus 
(BioForce Nanosciences, USA).  Wells were immediately attached post cleaning. 
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To attach wells with SU-8 photoresist, SU-8 was applied to the base of the well and the 
well was placed onto the substrate.  The substrate was then placed under UV light for 10 
min and baked at 65°C for 10 min.  An appreciable second layer of SU-8 was applied to 
the outside of the well base to prevent any leaks.  The substrate underwent a second 10 
min UV light exposure and 10 min bake at 65°C, followed by a final post bake at 90°C 
for 20 min.   
 
Additionally, wells were attached with the EponTM resin 828/Epikure 3140 two-part 
epoxy system.  Epon 828 and Epikure 3140 were mixed in a 1:1 (w/w) ratio and applied 
to the base of the well.  The well was placed on the substrate and then air dried overnight 
(~12 h).   
 
2.5.2 Nanocoax  
All electrochemical readouts of nanocoaxial arrays were carried out on a Reference 600 
potentiostat (Gamry Instruments, Warminster, PA) using a three-electrode system.  An 
external Ag/AgCl wire served as the reference electrode.  The outer Cr of the nanocoaxes 
in the array served as the counter electrode and the inner Au of the nanocoaxes 
functioned as the working electrode.  Electrochemical analysis of the nanocoaxial arrays 
was performed with DPV.   
 
2.5.3 Dendrites 
Electrochemical readouts were performed on a Reference 600 potentiostat or on a 
Reference 1000 potentiostat (Gamry Instruments, Warminster, PA) with a three-electrode 
56 
 
system.  An external Ag/AgCl wire served as the reference electrode and an external Pt 
wire functioned as the counter electrode.  The Au dendritic array served as the working 
electrode.  DPV was used as the method for electrochemical analysis of dendritic arrays.   
 
2.6 Enzyme-linked immunosorbent assay (ELISA) 
2.6.1 Electrochemical ELISA 
The wells of a 96-well plate were coated with 1 µg/ml of anti-cholera toxin Ab (anti-CT 
Ab) in 0.1 M NaHCO3, pH 9.6 for 2 h at room temperature.  The solution was removed 
from the plate and the wells were washed three times with TBST (0.05% Tween-20, 50 
mM Tris, 150 mM NaCl, pH 7.4); the wells were blocked with 5% BSA in TBST 
overnight at 4°C.  Several different concentrations of CT antigen in 2% BSA/TBST were 
added to individual wells and incubated for 1 h at room temperature.   The plate was then 
washed three times with TBST.  A second anti-CT Ab was added to each well at a 
concentration of 50 ng/ml in 2% BSA/TBST for 1 h at room temperature. The plate was 
washed three times with TBST.  Anti-mouse IgG alkaline phosphatase labeled Ab was 
added to each well at a dilution of 2.7 µg/ml in 2% BSA/TBST for 1 h at room 
temperature.  The plate was washed six times with TBST.  Lastly, the wells were 
incubated with 1 mM pAPP in TBS reaction buffer (50 mM Tris, 1 mM MgCl2, pH 9.0) 
at room temperature in the dark.  The reaction was stopped after 30 min by adding 40 µl 
of 50 mM EDTA in TBS to each well.  Approximately 100 µl of supernatant from each 
of the wells was then pipetted onto the nanostructure array for electrochemical 
measurements.  Electrochemical ELISA was analyzed via DPV; measurements were 
performed using a potential range of -0.3 V to 0.2 V, a potential step of 2 mV, a pulse 
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amplitude of 50 mV, a pulse width of 50 ms, a pulse sample period of 100 ms, and an 
equilibrium time of 10 s.   
 
2.6.2 Optical ELISA 
Optical ELISAs were performed in the exact same manner alongside electrochemical 
ELISAs, except that the BluePhos phosphatase substrate system replaced pAPP in the 
final step of the assay.  BluePhos was chosen over the traditional pNPP optical substrate 
due to its greater sensitivity.  The reaction was stopped after 30 min by adding 40 µl of 
50 mM EDTA to each well.  Optical absorbance was measured spectroscopically at 600 
nm on a SpectraMax M5 (Molecular Devices, Sunnyvale, CA).   
 
2.7 Data analysis 
DPV was the method used to measure electrochemical signal in the following studies.  
DPV is a pulsed voltammetric method that applies potential in a series of pulses 
superimposed over a staircase waveform.  This pulsing manner prevents charging 
currents and is therefore beneficial in electrochemical systems.  A generic potential 
waveform used in DPV is shown in Figure 2.7.1a.  The current is sampled before and 
after the pulse, and the difference between these values is the displayed current 
measurement in the DPV.  A typical resulting DPV is depicted in 2.7.1b, where the 
current is plotted against the potential.       
 
Electrochemical signal was analyzed by overlaying DPV signals of varying CT 
concentrations and determining the peak current of each DPV.  Raw DPV data was first 
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overlain as shown in Figure 2.7.2a in order to determine an appropriate potential at which 
to baseline the data.  DPV signals were baselined, or subtracted to zero, at a chosen 
potential that resulted in a smooth, overlapping baseline for the majority of the DPV 
signals and did not interfere in the oxidation curve (i.e. must  be baselined before the base 
of the curve appears).  An example of baselined DPV signals is shown in Figure 2.7.2b 
where the raw DPV data from Figure 2.7.2a has been subtracted to zero at -0.25 V.  Peak 
current (Ip) can now be determined for each DPV signal and subsequently plotted against 
their respective CT concentration to elucidate range of detection and limits of detection.   
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Figure 2.7.1.  DPV waveform and curve.  (a) Potential waveform used in DPV.  Potential 
is pulsed in increments along a staircase waveform.  X- axis: time (t); y-axis: potential 
(V).  (b) Typical resulting DPV curve, with a peak current (Ip) occurring at 0.3 V.  X-
axis: potential (V); y-axis: current (I). 
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Figure 2.7.2. DPV analysis. (a) Raw DPV data for several concentrations of CT during a 
CT ELISA.  (b) DPV signals subtracted to zero at -0.25 V to obtain a smooth, 
overlapping baseline in order to elucidate peak currents.  X-axis: potential (V); y-axis: 
current (I). 
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3.1 Introduction 
Much focus has been given to ultramicroelectrodes (UMEs) over the past couple of 
decades as a means to increase sensitivity of electrochemical sensors.  UMEs consist of 
electrodes with dimensions 25 µm or smaller, into the nanoscale regime.  Nanogap 
electrodes (UMEs with a nanogap separation between them) have especially drawn 
attention due to several perceived advantageous properties over their macroscale 
counterparts.  Nanogap electrodes have exhibited enhanced mass transport, decreased 
electric double layer capacitance (Cdl), and reduced solution resistance (Rs)
1–4.  The 
miniaturized dimensions of UMEs allow for radial diffusion and cycling of 
electrochemical reporter molecules between electrodes, producing a positive feedback 
loop and increasing signal.  Additionally, small Cdl and Rs constants allow for short time 
scales that are unfeasible in macroscopic electrodes.  Furthermore, exceptionally high 
current densities can be obtained with UMEs, whereas the currents themselves become 
very small, enabling improved signal-to-noise.  However, a major challenge associated 
with UMEs is a lack of fabrication techniques that provide reproducible, detailed 
structures, while remaining cost-effective and allowing for high-throughput fabrication. 
            
Previously, a novel nano-gapped UME structure, the nanocoax, was developed
5
.  The 
nanocoax resembles a vertically oriented coaxial electrode on the nanoscale.  It consists 
of two concentric electrodes separated by a nanogap composed of dielectric or air (Fig. 
3.1.1).  Due to the 3D, radial nature of the electrodes, the nanocoaxial structure can 
electrically interrogate higher volumes of sample within the WE-CE annulus gap over 
other conventional 2D and 3D vertical UMEs, leading to increased sensitivity.  We have 
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utilized nanoimprint lithography (NIL) to form the base SU-8 pillar array with which to 
construct nanocoax arrays.  NIL is a low-cost, rapid fabrication process that produces a 
large number of replicas from a single master6.  In addition, NIL enables uniform, 
reproducible structures and is well-suited for 3D nanostructures such as the vertical pillar 
array in the nanocoax architecture.  
 
The nanocoax previously demonstrated ultrasensitive chemical detection of volatile 
organic compounds
7
, and exhibited nanophotonic properties as a waveguide for visible 
light
5,8
.  Here, the nanocoax was investigated as an electrochemical biosensor in the 
detection of infectious disease biomarkers and compared to conventional protein 
detection methods.  ELISAs were performed using cholera toxin (CT) as the benchmark 
disease biomarker and electrochemically detected utilizing pulsed voltammetry methods 
on nanocoaxial arrays.   
 
  
 
64 
 
 
Figure 3.1.1. Structure of the nanocoax. (a) Schematic representation of a nanocoaxial 
array with an etched annulus.  The inner Au core (shown in yellow) serves as the working 
electrode (WE) and the outer Cr metal (gray) serves as the counter electrode (CE). (b) 
SEM images of an array with 150 nm annulus thickness and 500 nm annulus depth with 
inner Au and outer Cr electrodes.  SEM image taken at a 30° tilt.   
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3.2 Fabrication of nanocoaxial arrays 
Nanoimprint lithography (NIL) was used to construct the base SU-8 pillar array on a 
silicon substrate (Fig. 3.2.1a).  Previous iterations of the nanocoax utilized carbon 
nanotube arrays on Si as the base for nanocoax fabrication5,7; however non-uniformity 
and shorting between WE-CE were common problems with this method.  Conversely, 
NIL allows for highly structured and mechanically stable pillar arrays. 
 
To form the inner working electrode, the SU-8 pillars were coated with metal (Fig. 
3.2.1b): an adhesion layer of ~10 nm Ti was deposited immediately followed by ~125 nm 
Au via sputtering.  While Cr was also investigated as an inner electrode metal, all devices 
in this work were composed of Au inner electrodes due to the biocompatibility and 
electrochemical inertness of Au over a high potential range.  A dielectric layer of ~200 
nm Al2O3 was deposited with atomic layer deposition (ALD) in order to separate the 
inner and outer electrodes (Fig. 3.2.1c).  A metal coating of ~100 nm Cr was sputtered to 
form the outer counter electrode (Fig. 3.2.1d).  To aid in mechanical stability of the 
arrays, SU-8 was spin-coated to fill the gaps between each individual coax (Fig. 3.2.1e).  
Arrays underwent mechanical polishing in order to decapitate the outer metal layer and 
expose the dielectric layer (Fig. 3.2.1f).  Exposed dielectric was then wet-etched to form 
the hollow annulus to allow for electrochemical sensing between the outer and inner 
electrodes (Fig. 3.2.1g).     
   
SEMs of nanocoaxial arrays were taken to confirm proper mechanical structure (Fig. 
3.2.2a).  Successfully fabricated arrays consisted of nanocoaxes with 1.3 µm pitch and 2 
66 
 
µm height, and had nanocoax annuli that were 200 nm thick and 500 nm in depth.  All 
arrays had a circular base area of 1.8 mm2 as shown in Figure 3.2.2b.  Each array area 
contained ~106 individual nanocoaxes electrically connected in parallel.  Array areas 
were encapsulated within a polypropylene well using SU-8 epoxy (as described in 
Section 2.5.1) for reagent containment during electrochemical measurements (Fig. 
3.2.2c).  Additionally, gold wires were attached to electrode pads extending outside of the 
array area using a silver epoxy.  The wires were used to connect arrays in a circuit for 
electrochemical measurements.               
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Figure 3.2.1. Fabrication scheme of nanocoaxial arrays. (a) SU-8 nanopillar arrays, (b) 
inner metal coating, (c) dielectric deposition, (d) outer metal coating, (e) SU-8 polymer 
coating, (f) mechanical polishing, and (g) dielectric wet etch. 
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Figure 3.2.2. Fabricated nanocoaxial array. (a) SEM of a fully fabricated array (taken at a 
30° tilt). (b) Chip containing a nanocoaxial array with circular base area of 1.8 mm2, with 
pads for the WE and the CE extending to the ends of the chip. Penny for scale. (c) An 
array prepared for electrochemical measurements.  A polypropylene well was attached 
with SU8 over the array area for reagent containment.  Gold wires were attached to the 
WE pad and the CE pad using silver epoxy, providing a means to connect to a circuit.     
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3.3 Electrochemical set-up and measurements 
Electrochemical measurements with nanocoaxial arrays were performed using a three-
electrode system (Fig. 3.3.1a).  The inner gold electrode functioned as the working 
electrode (WE) and the outer Cr electrode functioned as the counter electrode (CE).  An 
external Ag/AgCl electrode served as the reference electrode (RE).  Differential pulse 
voltammetry (DPV) was chosen as the method for electrochemical analysis due to its 
suppression of background current and high sensitivity9.  A typical DPV waveform is 
depicted in Figure 3.3.1b for the oxidation of ferrocenecarboxylic acid (FCA).  Potential 
is swept across a specified range as a series of pulses and the resultant current is 
observed.  Ideally, current should remain unchanged until a redox reaction occurs, 
resulting in the peak at 0.3 V (as observed in Figure 3.3.1b) which is characteristic of 
FCA oxidation. By convention, an oxidation reaction at the WE produces an anodic 
current and the current is therefore designated negative.  Conversely, a reduction reaction 
produces a positively-denoted cathodic current.   
 
To confirm DPV as the optimal electrochemical method of choice, DPV was compared to 
square wave voltammetry (SWV).   SWV is another commonly used pulsed voltammetry 
technique exhibiting high sensitivity on a fast time scale10.  An alkaline phosphatase 
(ALP) dose titration was performed on a planar gold electrode (WE), with an external Pt 
CE and external Ag/AgCl RE.  ALP converts the enzymatic substrate p-aminophenol 
phosphate (pAPP) into the electrochemical reporter product 4-aminophenyl (4-AP), 
which is subsequently detected upon reaching its oxidation potential at -100 mV.  
Dilutions of ALP ranging from 5 pg/ml – 0.5 µg/ml were incubated with 1 mM pAPP.  
70 
 
The resultant enzymatic product 4-AP was electrochemically detected at -0.1 V by either 
SWV (Fig. 3.3.2a) or DPV (Fig. 3.3.2b).  DPV was performed with a potential range of -
0.3 to 0.2 V, a pulse size of 50 mV, a pulse time of 0.05 s, a step size of 2 mV, and a 
sample period of 0.1 s.  SWV was performed with a potential range of -0.3 to 0.2 V, a 
pulse size of 50 mV, and a frequency of 10 Hz.  These SWV and DPV parameters were 
previously optimized using FCA and ALP titrations.     
 
In order to determine the range of detection, peak current (I
p
) was plotted against ALP 
concentration on a log-scale for both methods (Fig. 3.3.3).  Peak currents were 
determined from the baseline normalized DPV and SWV signals, as shown in Figure 
3.3.3.  SWV signals were baselined at -0.25 V and DPV signals were baselined at -0.2 V.  
Both DPV and SWV exhibited ALP detection over a range of 500 pg/ml to 50 ng/ml, 
with a LOD of 500 pg/ml.  The dynamic range and LOD as measured by SWV was 
comparable to that of DPV, so DPV was continued as the method of choice for further 
nanocoaxial electrochemical measurements.  Additionally, the time scale for each 
optimized scan was on the order of ~10 s for both methods, eliminating any time 
advantage commonly associated with SWV.  All DPV measurements in the following 
work were performed with the same optimized parameters as used above.  Potential range 
was the only varied parameter and was adjusted accordingly, depending on the oxidation 
potential of the redox molecule to be detected.      
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Figure 3.3.1. Electrochemical set-up.  (a) Three-electrode system: inner metal (Au) of 
coaxial array served as WE, outer metal (Cr) served as CE, and an external Ag/AgCl wire 
served as RE. (b) Typical DPV waveform during the oxidation of FCA with Ag/AgCl as 
a RE.  X-axis: potential (V); y-axis: current (I).   
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Figure 3.3.2. Electrochemical detection of an ALP titration by (a) SWV and (b) DPV on 
a planar gold electrode. SWV signals were baselined at -0.25 V and DPV signals were 
baselined at -0.2 V.  X-axis: potential (V); y-axis: current (I).  Data represent one trial.     
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Figure 3.3.3.  Range of electrochemical detection for ALP by SWV (red) and DPV 
(black).  Peak current (I
p
) was plotted against ALP concentration on a log-scale to 
determine range of detection.  Peak currents were determined from the baseline 
normalized DPV and SWV signals as shown in Figure 3.3.2.  Data points were fitted with 
B-spline curves, excluding the outlier at 10 ng/ml ALP in the SWV curve.  Data represent 
one trial each for DPV and SWV.         
 
 
 
 
 
74 
 
3.4 Nanocoax for electrochemical sensing 
Previous iterations of the nanocoax demonstrated ultrasensitive detection of volatile 
organic compounds (VOCs) due to a change in capacitance in the presence of these 
chemical gases7.  Following this detection strategy, nanocoaxial capacitive sensing of 
biomolecules such as proteins was attempted; however, the presence of an electric double 
layer at the electrode/solution interface prevented the use of the nanocoax as a capacitive 
biosensor.  Therefore, electrochemical techniques (e.g. DPV, SWV) that suppress 
capacitive charge and non-faradaic current were used.       
 
To examine the potential of the nanocoax as an electrochemical sensor, DPV was 
employed to detect the oxidation of the redox species FCA.  FCA (along with other 
ferrocene derivatives) is a commonly-used redox reporter molecule in electrochemical 
studies, whose oxidation potential has been highly characterized11.  Nanocoaxial arrays of 
annulus thicknesses varying from 100 – 400 nm were investigated.  The WE-CE annulus 
gap was chosen as the variable parameter due to previously reported amplification in 
signal associated with a decreased electrode gap12,13.  A gold planar control of 
corresponding equivalent base area was examined to determine if the nanocoaxial 
architecture would improve signal over its macroscopic counterpart.  Wells encapsulating 
each array were filled with about 100 µl of 1 mM FCA in PBS, pH 7.4 in the 3-electrode 
configuration depicted in Figure 3.3.1a.  DPV was performed with a potential range of 
0.0 and 0.5 V to encompass the oxidation potential of FCA at 0.3 V.  We observed that 
current due to the oxidation of FCA increased with decreasing nanocoaxial annulus gap 
(Fig. 3.4.1a).  Moreover in all cases, nanocoaxial arrays displayed higher current than the 
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planar control.  Figure 3.4.1b quantitatively demonstrates the dependence of peak current 
on WE-CE annulus gap.  On the left y-axis, peak current (determined from DPV currents 
in Figure 3.4.1a) was plotted against the gap size (x-axis).  On the right y-axis, current 
densities of each array normalized to the planar control (Jcoax/Jplanar) were plotted against 
gap size (x-axis).  Current densities were determined by normalizing peak current to the 
sensor base area.  The data point at gap = 200 nm was the average of three separate 
nanocoaxial devices, with the error bar indicating the standard deviation.  At the smallest 
annulus gap (100 nm), the nanocoaxial array exhibited 90 times greater signal in response 
to the oxidation of FCA, as compared to the planar counterpart.  In addition, a significant 
improvement in signal-to-noise was observed, as the signal for the nanocoax was 
approximately 2 orders of magnitude greater than its planar counterpart, while the 
baseline noise level remained unchanged.   
 
This observed signal improvement in nanocoaxial arrays over the macroscale planar 
electrode may be attributed to redox cycling between closely spaced, nanogap electrode 
surfaces.  The nanoscale proximity between the WE and CE allows for dramatic 
amplification of signal by replenishing the redox species through reduction at the CE and 
rapid diffusion back to the WE.  Nanocoaxial arrays with smaller WE-CE gaps exhibited 
greater signal improvement, suggesting that as annulus gap decreases, the effect of redox 
cycling increases.  Furthermore, the concentric nature of the nanocoax structure allows 
for radial diffusion between the CE and WE.  As a consequence, many more redox 
molecules reach the WE than in the case of planar diffusion found in planar electrodes 
and 2D nanogap devices.  A final factor contributing to signal improvement may be the 
76 
 
high number of individual coaxes in the array.  Each 1.8 mm2 array contains ~106 coaxes 
connected in parallel, whose signals are additive. 
 
Although nanocoaxial arrays with 100 nm WE-CE gaps demonstrated the highest signal 
improvement, following studies utilized coaxes with a 200 nm gap due to limiting factors 
associated with the 100 nm gap.  WE-CE gaps of 100 nm exhibited difficulties with 
liquid loading during reagent exchange; this may be due to high surface tension at such a 
small gap, preventing reagent from properly diffusing into the annulus.  Coaxes with 50 
nm annulus gaps had been investigated and exhibited a decrease in current compared to 
100 nm gaps, suggesting that a threshold point had been reached in which the decreased 
WE-CE gap becomes detrimental.  In addition, yield of successful fabrication of 100 nm 
gap coaxial arrays was low, due to possible increased potential of shorting between the 
small electrode gap.  
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Figure 3.4.1. Electrochemical signal of nanocoaxial arrays with varying annulus 
thickness. (a) DPV signal of FCA oxidation on arrays with annuli varying from 100 to 
400 nm WE-CE gaps.  Planar counterpart with millimeter-scale CE-WE gap is also 
shown. X-axis: potential (V); y-axis: current (I). (b) Left y-axis: Peak currents (ΔI) vs. 
annulus WE-CE gap on the x-axis.  Right y-axis: nanocoaxial current density normalized 
to that of planar current density (Jcoax/Jplanar) vs. annulus WE-CE gap on the x-axis. At 
annulus gap = 200 nm, three measurements were taken on three different devices; error 
bars represent standard deviation.  All other data points represent one trial.  Taken from 
Ref 1414. 
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3.5 A nanocoaxial-based electrochemical biosensor 
Nanocoaxial arrays of 200 nm annulus gap were further investigated as electrochemical 
sensors to detect biological molecules.  All arrays underwent three steps of quality 
control before utilization in biological assays: SEM imaging, resistance measurements, 
and FCA oxidation signal.  As previously mentioned (in Section 3.2), SEM was used to 
assess if arrays appeared to be correctly fabricated structurally.  To confirm electrical 
integrity of each nanocoaxial array, resistance was measured between the working 
electrode and the counter electrode of each array.  Typical resistance values of devices 
used ranged from 10 - 100 GΩ.  Arrays with resistance below the MΩ regime were 
disregarded due to potential shorting issues.  Nanocoaxial arrays were additionally tested 
with the redox species FCA to confirm electrochemical sensing capabilities.  DPVs were 
performed with 1 mM FCA in PBS, pH 7.4 over a potential range of 0 to 0.5 V.  DPV 
signals varied from -60 to -150 µA between arrays.   
 
Batch-to-batch variation between arrays was observed with these quality control tests.  
Most notably in Figure 3.5.1, lower DPV current signals (-60 to -80 µA) corresponded to 
arrays with non-decapitated, intact inner electrodes (Fig. 3.5.1b).   Higher DPV current 
signals (-150 µA) were observed with arrays whose inner electrode has been decapitated 
to expose the underlying SU-8 pillar (Fig. 3.5.1c).  A possible explanation for this 
discrepancy may be due to increased hydrophilicity of SU-8 exposed nanocoaxes after 
pre-treatment with UV-ozone; all arrays underwent a UV/ozone cleaning pre-treatment 
before use, and treatment of SU-8 with ozone opens up residual epoxide rings in the 
polymer, dramatically increasing hydrophilicity15.  This could provide decreased surface 
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tension at the annulus on coaxes with exposed inner SU-8 pillars and therefore allow 
more reagent into the gap.  Because of this signal enhancement, all of the following 
electrochemical measurements were performed on arrays with decapitated, SU-8 exposed 
inner electrodes.  The exception was the ALP titration in Figure 3.5.2 which was 
performed on an array with non-decapitated inner electrodes; this was due to the fact that 
this structural-dependent difference in FCA current signal had not yet been observed.   
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Figure 3.5.1. Electrochemical characterization of nanocoaxial arrays. (a) DPV signals of 
FCA oxidation on several arrays. Y-axis: current (I); x-axis: potential (V).  (b) SEM of 
arrays with intact inner electrodes and (c) decapitated inner electrodes.  Scale bars 
represent 1 µm; SEM images taken at a 30° tilt. 
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Next, an ALP titration was performed and DPVs were recorded on the nanocoax for 
proof-of-concept of a nanocoaxial-based electrochemical ELISA.  Serial dilutions of ALP 
were incubated with 1 mM of the enzymatic substrate pAPP and then electrochemically 
examined on the nanocoax (Fig. 3.5.2a), as well as on a planar gold electrode to compare 
the nanocoaxial architecture for ALP detection to its macroscale counterpart (Fig. 
3.5.2b). Each set of titration data (nanocoax and planar) was taken on a single device.  
Runs on additional devices gave qualitatively similar results; however, it was noted that 
some devices exhibited no electrochemical signal, likely due to shorting and fabrication 
issues.  With the planar gold device, an ALP concentration of 10-3 ng/ml was required to 
measure an appreciable signal change from baseline at the -100 mV region.  However, 
the nanocoax exhibited a noticeable current peak from baseline starting at an ALP 
concentration of 10-6 ng/ml (i.e. 103x more sensitive).   
 
To determine the range of detection, peak current was normalized to the base area of each 
sensor (J) and plotted against ALP concentration (Fig. 3.5.3).  At all concentrations the 
planar gold device exhibited appreciably lower overall current magnitude compared to 
the nanocoax.  In addition, the nanocoax exhibited a greater dynamic range, over the ALP 
concentrations of 10-6 - 1 ng/ml.  The planar counterpart, on the other hand, exhibited 
only a two decade dynamic range from 10-4 - 10-2 ng/ml ALP, trending toward saturation 
at the upper end and a lower limit of detection at 10-4 ng/ml ALP.  It is worth noting that 
the true “active” area of the nanocoaxial array (i.e. the inner core/working electrode 
within each coax) is only a fraction (about 1/4) of the array’s base area to which the 
current was normalized; yet the electrochemical signal from the nanocoax still surpassed 
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that of the planar device whose entire base area constitutes its working electrode.  
Therefore, this ALP titration highlights not only proof-of-concept for an electrochemical 
ELISA on the nanocoax, but also the significant advantage of the nanocoaxial structure 
over its planar counterpart towards greater electrochemical sensing capabilities. 
 
We next developed an electrochemical ELISA for detection of cholera toxin (CT).  CT 
was chosen as the benchmark disease biomarker due to its clinical relevance in water-
borne infectious diseases16.  In addition, the non-toxic B subunit of CT was utilized, 
which allowed for ease of handling.  The CT ELISA was optimized identically for both 
optical and electrochemical readouts.  All steps were performed in the same manner, 
except in the final step where the reporter molecule was added; Bluephos was added for 
optical readout, whereas pAPP was added for electrochemical readout.  EDTA was 
chosen as the stop solution to quench the ALP reaction due to its ability to quench both 
optical and electrochemical ELISAs without interfering in readout; other stop solutions 
examined, such as sodium hydroxide, interfered with electrochemical readout.     
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Figure 3.5.2. DPV signals of an ALP titration on (a) a nanocoaxial array and (b) a planar 
gold counterpart.  DPV signals were subtracted to baseline at -0.2 V.  X-axis: potential 
(V); y-axis: current (I).   
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Figure 3.5.3. Detection range of ALP titration by nanocoax (blue) and planar Au sensor 
(red).  On the y-axis, current density (J) was plotted against the log-scale of ALP 
concentration (x-axis).  Current density was determined by normalizing peak current 
(from Figure 3.5.2) to base area of each sensor.  Data represent one trial each.   
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ELISA reactions were performed externally in a 96-well plate and completed assay 
supernatants were then applied to the nanocoaxial array.  The ELISA was run in duplicate 
with staggered replicates.  All steps of the ELISA were run in parallel in both replicates 
until the final step: addition of 1 mM pAPP.  1 mM pAPP in TBS, pH 9 was added to the 
first replicate (R1), while TBST, pH 7.4 was added to the second replicate (R2).  The 
ELISA proceeded to completion in R1, and DPVs were immediately recorded for R1 
using the same parameters previously mentioned.  Buffer was then removed from R2 and 
1 mM pAPP in TBS, pH 9 was added to complete the assay.  DPVs were then 
subsequently recorded for R2 on the same device.  The replicates were staggered in such 
a manner due to previously observed degradation of 4-AP (the final redox product of the 
ELISA); the staggered replicates attempted to prevent any 4-AP degradation in R2 that 
would occur from increased wait time before DPV measurements.    
 
Figure 3.5.4 shows the DPV signals obtained for both replicates of a staggered 
electrochemical ELISA, with the current subtracted to baseline at -0.2 V to determine 
peak current.  CT concentrations ranging from 1 ng/ml to 10 µg/ml were examined.  Both 
replicates produced discernable current peaks at all CT concentrations, however the DPV 
signal for the “No CT” control exhibited a noticeable current peak as well.  This 
suggested non-specific binding of the ALP-labeled antibody; therefore, the detection 
antibody concentration was adjusted accordingly to a lower concentration in all following 
ELISAs.  In addition, R1 (Fig. 3.5.4a) did not demonstrate the smooth, overlapping DPV 
baselines as seen in R2 (Fig. 3.5.4b).  The first DPV signal in R1 (“No CT” 
measurement) exhibited significant drift, resulting in a deviating baseline from other 
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DPV signals.  However, this drift eventually faded in subsequent R1 measurements as 
indicated by uniform, overlapping baselines, and was not present in any R2 
measurements.  This suggested that coaxial devices may need to be electrically 
preconditioned before use.  Preconditioning is thought to remove any remaining 
contaminants and “warm up” the electrode17,18.  Therefore, all future measurements were 
preceded by 3-5 DPV runs in TBS buffer to alleviate any effects from drift.    
    
To determine the dynamic range, peak current was plotted against the CT concentration 
on a log scale (Fig. 3.5.5a).  Peak current was determined from DPV signals in Figure 
3.5.4 that were baselined at -0.2 V.  A log-linear dynamic range of 4 ng/ml - 100 ng/ml 
(R2 ≥ 0.95) was observed, with a lower LOD of 1 ng/ml.  The effect of drift in R1 is 
further emphasized in Figure 3.5.5a; both replicates qualitatively exhibited the same 
range of detection, however at lower concentrations in R1, current signals were 
quantitatively lower until the drift effect fell off after a few measurements on the device.   
 
In addition, the electrochemical nanocoaxial sensor was compared to the conventional 
optical ELISA as a standard control.  The optical ELISA was performed in the same 
manner as the electrochemical ELISA, with the exception that the BluePhos substrate 
was used in place of pAPP.  BluePhos is converted by ALP into a colorimetric product, 
whose optical absorbance is read at λmax=600 nm.  In Figure 3.5.5b, CT concentration 
was plotted against absorbance; the optical readout exhibited a log-linear range of 
detection from 2 ng/ml - 100 ng/ml (R2 ≥ 0.95), with a lower LOD of 1 ng/ml.  Here, 
electrochemical detection with the nanocoax and the standard optical readout exhibited 
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essentially the same range of detection and LOD.  However, as seen in Figure 3.5.5, the 
lower end had not yet trended to a zero value in either the electrochemical or optical 
readouts, suggesting that both methods are capable of CT detection beyond the range of 
CT investigated.  Following experiments increased the lower range beyond 1 ng/ml to 
discover the true LOD of each method. 
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Figure 3.5.4. DPV signals of a staggered CT ELISA on a nanocoaxial array for (a) 
replicate 1 (R1) and (b) replicate 2 (R2).  Both replicates were measured on the same 
device.  Current subtracted to baseline at -0.2 V.  X-axis: potential (V); y-axis: current (I). 
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Figure 3.5.5. Detection range of staggered CT ELISA by electrochemical and optical 
methods. (a) Electrochemical readout on nanocoax: peak current (-Ip) of staggered 
replicates (R1 and R2) on the y-axis vs. log-scale of CT concentration on the x-axis. Both 
replicates measured on the same nanocoaxial device.  (b) Optical readout: absorbance at 
600 nm (y-axis) vs. log-scale of CT concentration (x-axis). Data represent one trial.  
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Reusability and reproducibility of nanocoaxial arrays were examined with the same 
device used in Figure 3.5.6.  Another CT ELISA was performed and DPVs were recorded 
(Fig. 3.5.6a).  The device was preconditioned with three DPV runs of TBS, pH 9 prior to 
the measurement of ELISA reactions in order to alleviate drift.  Successful 
preconditioning was demonstrated by a smooth, overlapping DPV baseline after the final 
run of TBS (yellow line in Fig. 3.5.6a).  To assess reproducibility, three subsequent 
measurements were taken for 2x10-2 µg/ml.  It should be noted that the “No CT” and 10-3 
µg/ml CT concentrations were not shown; data were initially recorded on a different 
device that shorted midway through the experiment, depleting the ELISA reactions for 
those concentrations.  Range of detection was determined by plotting peak current against 
CT concentration (Fig. 3.5.6b); the device detected CT from 10-2 to 1 µg/ml, with a LOD 
of 10-2 µg/ml, whereas previously the same device had detected CT from 4x10-3 to 10-1 
µg/ml with a LOD of 10-3 µg/ml.  In both ELISAs, the device detected CT across a range 
of 3 orders of magnitude; however during reuse, the device was less sensitive at the lower 
end range and the range shifted up an order of magnitude.  Despite degradation of signal 
at lower CT concentrations, statistical analysis of the replicate data at 2x10-2 µg/ml 
indicates significant reproducibility of measurements on a single nanocoaxial device.   
These results indicated that the device was capable of being reused for multiple ELISAs; 
however, a degradation of sensitivity at lower concentrations observed over time shifted 
the range of detection.  
 
Electrochemical detection of CT by nanocoaxial arrays was further analyzed with an 
increased range of CT concentrations to determine the true range and LOD.  ELISAs 
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were performed in duplicate and both replicates were electrochemically measured 
concurrently on the same device.  Identical CT concentrations in both replicates were 
measured in parallel as opposed to measuring all of R1 first and then R2 as was done 
with a staggered ELISA.  Degradation effects of 4-AP between replicates were 
significantly minimized in this manner.  In addition, any variation in the addition of 
pAPP to R1 and R2 in staggered stages was eliminated.  Figure 3.5.7 shows the DPV 
signals obtained from a non-staggered ELISA run in duplicate, with the current 
subtracted to baseline at -0.15 V to elucidate peak current. To determine the dynamic 
range, peak current was plotted against the CT concentration on the log scale (Fig. 3.5.8).  
Here, we observed a log-linear dynamic range of 10 ng/ml - 1 µg/ml (R2 ≥ 0.95), with a 
lower LOD of 2 ng/ml (as determined by LOD = Ip,control + 3σcontrol ; control = No CT 
sample).  Statistical analysis of the replicate data indicates significant reproducibility of 
measurements on a single nanocoaxial device.  It should be noted that error bars 
representing standard deviation are present at every CT concentration in Figure 3.5.8; 
however in most cases, the error bars were smaller than the graphed data points 
themselves.    
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 Figure 3.5.6. Reusability of nanocoaxial arrays. (a) DPV signals of a CT ELISA on a 
previously used coaxial array.  DPV signals were subtracted to baseline at -0.2 V.  Three 
replicates were performed at [CT] = 2x10-2 µg/ml. X-axis: potential (V); y-axis: current 
(I). (b) Peak current (-Ip) on the y-axis vs. log-scale of CT concentration on the x-axis.  
Peak currents were determined from baselined DPV signals in Figure 3.5.6a.  Error bar at 
[CT] = 2x10-2 µg/ml represents standard deviation.  All other data points represent one 
trial.    
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Figure 3.5.7. DPV signals of a non-staggered ELISA. (a) First replicate (R1) and (b) 
second replicate (R2) were measured in parallel on the same nanocoax device.  DPVs 
were subtracted to baseline at -0.14 V.  X-axis: potential (V); y-axis: current (I). 
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Figure 3.5.8. Detection range of a non-staggered ELISA on a nanocoax.  Peak current (-
Ip) (y-axis) vs. log-scale of CT concentration (x-axis) from a non-staggered ELISA.  Peak 
currents were determined from baselined DPV signals in Figure 3.5.7.  Data points 
represent average of duplicates (R1 and R2); error bars represent standard deviation.   
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In addition, electrochemical detection with the nanocoaxial sensor was compared to the 
conventional optical ELISA as a standard control.  The optical ELISA was carried out in 
duplicate and the results are shown in Figure 3.5.9 on the right y-axis, with absorbance 
plotted against CT concentration.  On the left y-axis of Figure 3.5.9, peak current was 
plotted against CT concentration (peak currents were determined from Figure 3.5.7).  The 
optical readout was linear over a dynamic range of 10 ng/ml to 1 µg/ml, with a LOD of 1 
ng/ml.  Electrochemical detection was linear over the same dynamic range of 10 ng/ml to 
1 µg/ml and exhibited a similar LOD of 2 ng/ml. These results indicated that the 
nanocoaxial electrochemical sensor is comparable to the standard optical ELISA with 
respect to the linear dynamic range of detection and exhibited a LOD on the same order 
of magnitude (2 ng/ml vs. 1 ng/ml). 
 
It was observed that the DPV signal from the oxidation of 1 mM FCA degraded over 
multiple measurements, despite exchanging FCA reagent in between each 
measurement19.  While devices had an initial current of -80 to -150 µA (depending on 
inner electrode structure) during FCA oxidation, subsequent measurements on all arrays 
exhibited a decrease in current and an eventual stabilization at -25 to -30 µA.  However, 
as demonstrated in Figures 3.5.5 and 3.5.8, nanocoaxial arrays were able to 
electrochemically detect CT with comparable sensitivity to the conventional optical 
readout.  These results indicated that the current saturation observed with FCA was an 
effect independent of ELISA performance (i.e. the oxidation of 4-AP).   
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To confirm this observation, DPVs of a CT ELISA were performed on an array that had 
not been previously FCA tested (Fig. 3.5.10a).  Four DPVs were performed with 1 mM 
FCA after ELISA measurements had been already been recorded.  The initial FCA 
current signal was ~ -90 µA, which fell in the characteristic range of initial FCA tests on 
coaxial arrays.  Subsequent DPV measurements exhibited a decrease in current and 
eventual stabilization at ~ -25 µA.  In addition, DPV signals of FCA oxidation were taken 
on another separate array before and after an ELISA was electrochemically measured 
(Fig. 3.5.10b).  The FCA response recorded before ELISA measurements was ~ -110 µA, 
~ -25 µA after the first ELISA replicate (R1), and ~ -25 µA after the second ELISA 
replicate (R2).  Both replicates (R1 and R2) detected CT over the same range and 
exhibited the same LOD with comparable peak currents (as seen in Figure 3.5.5a), 
despite the change in FCA current from -110 µA before R1 to -25 µA before R2 
measurements.  Moreover, both of these devices reproducibly detected CT over a similar 
range (~1 ng/ml – 1 µg/ml) and LOD (~ 1 ng/ml), regardless of whether FCA oxidation 
current was around -100 µA or stabilized at -25 µA before ELISA measurements.  This 
strongly suggests that the signal degradation of FCA is independent of ELISA 
performance and may be a molecule specific phenomenon that does not necessarily 
indicate device degradation.                  
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Figure 3.5.9.  Electrochemical and optical readouts of a CT ELISA.  On the right y-axis, 
peak current (Ip) vs. CT concentration (x-axis) is plotted for electrochemical detection by 
the nanocoaxial array (red).  Peak currents were determined from the baselined DPV 
signals as shown in Figure 3.5.7.  Data represents two trials run on the same device; error 
bar shown is the standard deviation.  On the left y-axis, absorbance at λ = 600 nm is 
plotted against CT concentration (x-axis) for the conventional optical readout of an 
ELISA (blue).  Data represent two trials.  Error bar shown is the standard deviation.   
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Figure 3.5.10. FCA degradation on nanocoaxial arrays independent of ELISA 
performance. (a) DPVs of 1 mM FCA on a nanocoaxial device that has already 
undergone ELISA measurements without any previous FCA testing. (b) DPVs of 1 mM 
FCA on a device before and after ELISA measurements run in duplicate (R1: replicate 1; 
R2: replicate 2). Y-axis: potential (V); x-axis: current (I). 
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3.6 Future directions: extended core coax   
We have demonstrated electrochemical nanocoaxial detection of CT with sensitivity 
comparable to the conventional optical readout.  However two issues inhibit the 
nanocoax from further development into a POC device: diffusion of reagent into the 
annulus gap and liquid loading/exchange.  Difficulties with reagent diffusion into the 
annulus gap due to surface tension was observed with increasingly small annuli gaps, 
inhibiting redox molecules from diffusing between the electrodes for electrochemical 
measurements and thus lowering sensitivity.  In addition, once reagent was inside the 
gap, liquid exchange of reagents was extremely hindered, if not impossible.  Ethanol 
washes followed by N2 drying were required to remove reagent between measurements.  
However in a POC device, ELISA reagents (e.g. CT antibody) would ideally be tethered 
to the inner electrode; this requirement for ethanol washes in between steps is not 
amenable to biofunctionalization as ethanol would denature and disrupt protein 
interactions.  
 
A next generation coaxial device, the extended core coax (ECC), is also currently being 
developed to overcome these obstacles.  The ECC retains the nanocoaxial architecture, 
however the inner electrode extends some distance (e.g. 200 nm) above the outer 
electrode.  Moreover, annulus depth has been lessened to 200 nm from the previous 500 
nm depth, with the prospect of eliminating any depth altogether.  Together, these two 
factors should reduce surface tension between electrodes and allow for proper liquid 
exchange.  Moreover, the extended core structure would allow for biofunctionalization 
and advance the nanocoaxial architecture towards POC potential.  The ECC architecture 
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could allow for a highly-effective flow-through device, where reagent entry into the 
annulus is not required, yet the nanoscale proximity (WE-CE) advantage is maintained.    
 
ECC arrays were fabricated by similar methods as first generation nanocoaxial arrays.   
Si pillar arrays served as the base substrate, and were coated with a 10 nm Ti adhesion 
layer, followed by 110 nm Au to form the inner electrode.  A dielectric layer of 150 nm 
Al2O3 was deposited via ALD, followed by sputter deposition of 125 nm Cr to form the 
outer electrode. Cr and Al2O3 were then wet-etched away to expose the extended gold 
core and form the dielectric annulus with a 200 nm depth.  Figure 3.6.1a shows a SEM 
image of a fully fabricated ECC array.  These arrays have a base area of 0.2 mm2 (d= 500 
µm) and contain ~105 individual coaxes, compared to the 1.8 mm2 base area of first 
generation arrays (d = 1.5 mm), which contained ~106 coaxes.  In addition, a single chip 
of 16 x 30 mm2 area has ten independently addressed arrays (with the ability to 
accommodate more), providing a platform amenable to multiplexing for the detection of 
multiple disease biomarkers simultaneously.   
 
To examine the potential of the ECC architecture for electrochemical sensing, DPVs 
were performed to detect the oxidation of 1 mM FCA (Fig. 3.6.1b).  Multiple DPV 
measurements exhibited similar current signals, with an average peak current of 
approximately -30 µA.  Subsequent runs exhibited smoother curves, suggesting a similar 
requirement for preconditioning as the previous coax iteration.  Current densities (J) were 
calculated for the ECC and for the first generation nanocoax to compare electrochemical 
performance (Fig. 3.6.2); a planar Au control was examined as well.  Current densities 
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were determined by dividing the peak current from Figure 3.6.1b by the array base area.  
Current density for the nanocoax was calculated using -150 µA, the highest peak current 
obtained from FCA oxidation on a first generation array.  The ECC array exhibited a 
current density of 150 µA/mm2 and the nanocoaxial array exhibited a current density of 
83 µA/mm2.  Planar Au controls exhibited a current density of 5 µA/mm2.  The ECC 
array exhibited an approximate 2-fold increase in current density over the nanocoax, with 
an array base area 9x smaller.         
          
The increased current density of the ECC array could allow for improved sensitivity in 
the electrochemical detection of biomarkers over the first generation nanocoax.  
Additionally, ECC arrays provide a platform amenable to biofunctionalization and 
multiplexing.  Further studies (ALP dose titrations, ELISAs) with the ECC arrays will be 
completed to determine if the increased current density corresponds to improved 
sensitivity.  If sensitivity is not improved, the ECC will still provide advantages over the 
first generation nanocoax.  The extended core will allow for biofunctionalization of 
receptor protein directly onto the inner electrode, and the small array areas would allow 
for facile multiplexing for multiple disease biomarkers on a single portable chip.  
Together, these factors could advance the nanocoaxial architecture towards a true POC 
device. 
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Figure 3.6.1. Extended core coax. (a) SEM of an ECC array (taken at 30° tilt), with an 
inner Au core as the WE and an outer Cr CE. (b) DPV signals of 1 mM FCA on an ECC 
array.  DPVs were measured on the same device.  X-axis: potential (V); y-axis: current 
(I). 
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Figure 3.6.2. Current densities (J) of planar Au, nanocoax and ECC during the oxidation 
of 1 mM FCA. Current densities were determined by dividing DPV peak current by array 
base area.  
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Summary 
Nanocoaxial-based arrays have been fabricated and developed as electrochemical 
biosensors for the detection of the infectious disease biomarker, CT.  The decreasing 
nanoscale proximity between the working and counter electrodes has been shown to be 
advantageous in enhancing electrochemical signal, with an optimal WE-CE gap of 200 
nm.  Nanocoaxial detection of alkaline phosphatase titrations provided proof-of-concept 
for an electrochemical ELISA, and demonstrated increased sensitivity over its planar 
electrode counterpart.  The nanocoax exhibited electrochemical detection of a CT ELISA 
comparable to the standard optical ELISA with regard to dynamic range and LOD.  Both 
nanocoaxial electrochemical readout and the optical readout exhibited a log-linear range 
of detection over the CT concentrations of 10 ng/ml to 1 µg/ml.  Nanocoaxial arrays 
demonstrated a LOD of 2 ng/ml, on the same order as the optical readout whose LOD 
was 1 ng/ml.   
 
The electrochemical readout of the nanocoax matches the performance of the optical 
readout, while providing advantages over the conventional ELISA towards further 
development to POC applications.  Nanocoaxial-based sensors allow for a simple 
electrical readout that utilizes less reagent and provides a miniaturized platform amenable 
to multiplexing for the detection of multiple disease biomarkers simultaneously.  With 
further development and characterization of the extended core coax architecture, 
nanocoaxial sensors will have high potential towards use in POC devices. 
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4.1 Introduction 
Metallic dendrites represent another type of electrode gaining attention as sensitive 
electrochemical sensors.  Metallic dendrites are crystals with tree-like branching 
structures, and can be composed of a single metal or an alloy1.  Dendrites are an attractive 
class of materials for electrochemical sensors due to their high surface-area-to-volume 
ratio.  This increase in surface area facilitates larger numbers of biomolecular events at 
the electrode surface, promoting high levels of collisions with target analytes and higher 
rates of diffusion.  Additionally, the increased surface area enhances the amount of probe 
molecules that can be attached onto the sensor electrode for target capture.  This property 
makes dendritic structures appealing in a wide variety of applications, including 
catalysis2,3, chemical sensing4,5, and electrochemical sensing6,7.  Historically, dendrites 
have typically been fabricated as dispersed particles in solution, and therefore require 
several final processing steps to produce a properly oriented product on an electrode 
surface3,5,8.   
 
Directed electrochemical nanowire assembly (DENA) is a one-step, high growth rate 
technique to produce oriented, single-crystal metallic nanowires and dendrites from an 
electrode surface9, eliminating the need for additional end processing steps.  An 
alternating electric field in the presence of a salt solution induces the crystallization of the 
nanowires or dendrites onto an electrode in solution.  The direction of growth and 
orientation of the structure is determined by the electric field and electrode 
configuration10,11.  DENA was first performed by Cheng et al.12 for the growth of Pd 
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nanowires; since then, DENA has been utilized for the fabrication of nanowires and 
dendrites composed of various metallic crystals such as Ag5, Au1, Pt13, Cu14, and In15.   
Recently, dendritic structures have been applied in electrochemical biosensing for the 
detection of disease biomarkers16.  For example, Kelley et al.17 demonstrated sensitive 
and specific electrochemical detection of the cancer biomarker CA-125 with dendritic 
structures ranging from 30 to 100 µm in size and exhibiting a detection range of 0.1 to 
100 U/ml.  This range and limit of detection is comparable to the standard ELISA method 
of protein detection. Moreover, these micron-scaled dendritic structures are capable of 
being integrated into multiple arrays on a single chip, allowing for multiplexed detection 
of multiple disease markers.  Kelley et al.18 also created a panel for nucleic acid cancer 
biomarkers on a multiplexed dendritic electrode platform.  The dendritic array 
demonstrated simple, highly sensitive detection of mRNA from several prostate tumor 
cell lines with lower limits of 10 ng mRNA, and in under a 1 h total processing time.   
 
Here, we applied DENA to fabricate nanostructured gold dendrites on varying base 
substrates and evaluated dendritic-based arrays as electrochemical sensors for the 
detection of disease biomarkers.  A typical dendritic array used in electrochemical 
sensing is depicted in Figure 4.1.1.  ELISAs were performed using cholera toxin (CT) as 
the benchmark disease biomarker and were electrochemically detected utilizing pulsed 
voltammetry methods on the dendritic arrays.  
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Figure 4.1.1. SEM of gold nanostructured dendrites fabricated by DENA on an Au-
coated Si pillar array. 
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4.2 Fabrication of dendritic arrays 
Dendritic arrays were fabricated using directed electrochemical nanowire assembly 
(DENA).  Au-coated base substrates served as the working electrode (WE) onto which 
dendrites were grown; these base substrates included planar Au, Au-coated Si pillar 
arrays, and the inner Au core of previously described nanocoaxial structures (Ch. 3).  
DENA was performed using a square waveform and alternating current, with the 
substrate submerged in 30 mM chloroauric acid (HAuCl4) solution across from a counter 
electrode (CE).  The CE was composed of either a Pt wire or a planar Au chip in all 
DENA processes, depending on availability.  Distance between the working and counter 
electrodes was varied for optimal dendritic growth, as discussed later in Section 4.5.  The 
waveform was carried out with a frequency of 30 MHz, an amplitude of 5 Vpp, an offset 
of -1.25 Vo, a phase of 0, and a duty cycle of 50% for 20 min.  A schematic of the square 
waveform is illustrated in Figure 4.2.1a.  The working electrode (WE) was negatively 
biased by the voltage offset in order to seed and promote dendritic crystalline growth of 
Au3+ cations at the base gold substrate.  Frequency, amplitude, and offset were varied to 
determine the optimal parameters, as discussed below.  However, the above parameters 
were determined optimal for dendritic growth, and are the parameters used in the 
following experiments unless otherwise stated.  
 
Two different setups were utilized with which to perform DENA processes.  Initially, 
dendritic structures were grown on the micro-scale setup as illustrated in Figure 4.2.1b.  
Wells were attached to substrates prior to dendrite growth in order to form a reagent 
reservoir for the ~100 µl of HAuCl4 solution used during DENA.  An external Pt wire 
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served as the CE and was set in the well at a distance of 100 µm from the WE.  Later 
growth conditions were performed on a macro-scale setup, schematically represented in 
Figure 4.2.1c.  The gold substrate was placed vertically in ~25 ml of HAuCl4 solution 
across from a CE (e.g. Pt wire, planar Au) at a distance of about 25 mm.  In this setup, 
DENA was performed prior to well attachment; this allowed for SEM analysis of DENA 
samples to confirm dendrite fabrication prior to any electrochemical measurements.  With 
the micro-scale setup, dendritic structures could only be interrogated via SEM after 
biological assays were performed and the well had been permanently removed.  
 
Dendrites were grown on different starting base substrates in order to fabricate either 
planar dendritic arrays or 3D dendritic arrays.  Au-coated planar Si was used as the base 
substrate to create planar dendrites.  An SEM of planar dendrites is shown in Figure 
4.2.2a.  On the other hand, Au-coated Si pillars (Figure 4.2.2b) were used as the base 
substrate to fabricate 3D dendrites. An SEM of 3D dendrites is depicted in Figure 4.2.2c.  
Planar dendrites tended to exhibit flatter, more granular, and more widespread growth; 
3D dendrites grew in a more upward fashion, with crystals extending tens to hundreds of 
microns above the pillar base.  Planar dendrites were characterized by a bulky “boulder” 
look, whereas the 3D dendrites resembled “trees” rooted on the pillar tips.  The difference 
in structure can be attributed to electric fields that concentrate at sharp edges and points.  
On the planar substrate, the electric field is evenly distributed due to the absence of points 
or edges, and therefore promotes unbiased dendritic growth throughout the entire sample.  
This resulted in the observed flat, widespread dendrite growth characteristic of planar 
base samples.  Conversely, the pillar arrays provided a concentrated electric field at the 
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tips of each pillar, favoring dendrite growth solely at the pillar tips.  This is further 
corroborated by the lack of any dendritic growth at the base of the pillars in the 3D 
dendrite samples. 
 
Dendritic growth could be initially confirmed by eye; the substrate exhibited a rust-like 
color on the area where DENA has been performed.  This color change can be seen in 
Figure 4.2.3a where 3D dendrites have been grown on a Au-coated Si pillar array.  The 
well has been removed, leaving behind a residual epoxy ring and revealing a dark brown 
region of dendrites.  The physical change in sample appearance is striking in comparison 
to the pillar region outside of the well’s epoxy ring.  To prepare samples for 
electrochemical measurements, dendritic array areas were encapsulated within a 
polypropylene well using SU-8 epoxy for reagent containment.  Additionally, gold wire 
was attached to the chip on an area outside of the array area using silver epoxy.  The wire 
was used to connect arrays in a circuit for electrochemical measurements.  A 3D dendritic 
sample that is fully prepared for electrochemical assays is depicted in Figure 4.2.3b.   
 
SEM was used to examine the growth and structure of the fabricated dendrites.  Dendritic 
growth was defined by uniform coverage of dendritic structure across the entire sample 
area as seen in Figure 4.2.4a.  Additionally, growth was characterized by highly branched 
structures that were tall and highly extending (Figure 4.2.4b).  Well-fabricated 3D 
dendrites exhibited extending structures that were tens to hundreds of microns tall above 
the pillar base.  Conversely, limited dendritic growth demonstrated non-uniform, sparse 
coverage of the substrate area.  As shown in Figure 4.2.4c, dendrite growth is varied 
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throughout the sample; denser growth is concentrated around the outer circumference, 
and sparse growth is located in the central region of the substrate.  Additionally, low 
growth resulted in very limited branching of dendrites, and non-extending structures as 
seen in Figure 4.2.4d.  3D dendrites were drastically shortened when conditions produced 
limited growth.  Optimization of conditions to routinely fabricate uniformly covered 
samples with highly-branched, highly-extending dendrites is discussed in Section 4.5.    
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Figure 4.2.1. DENA fabrication scheme. (a) Schematic of a typical square waveform 
used during DENA with an amplitude of 5 Vpp, an offset of -1.25 Vo, a phase of 0, and a 
duty cycle of 50%. (b) Micro-scale setup for dendritic growth on a gold WE (e.g. planar, 
pillars) with an external Pt wire functioning as the CE. (c) Macro-scale setup for dendritic 
growth on a gold WE (e.g. planar, pillars) with a parallel CE (e.g. Pt wire, planar Au).  
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Figure 4.2.2. SEMs of dendritic samples fabricated by DENA. (a) Planar dendrites 
grown on a Au-coated planar Si substrate. (b) Au-coated Si pillar array with pillars 2 µm 
in height that served as the base substrate for 3D dendrites. (c) 3D dendrites grown on a 
Au-coated Si pillar array.  Scale bars represent 1 µm.  SEMs taken at 30° tilt. 
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Figure 4.2.3. Dendritic sample preparation. (a) A 3D dendritic sample after DENA has 
been performed and the well has been removed.  A residual ring of epoxy has been left 
behind from the well removal.  Dendritic growth can be visualized by eye due to the 
presence of a rusty color (in the circular area).  (b) A 3D dendritic array prepared for 
electrochemical measurements. A polypropylene well was attached over the array area 
for reagent containment.  Gold wire was attached to the chip on an area outside of the 
array using Ag epoxy.  
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Figure 4.2.4. SEMs of variations in dendritic growth. (a) Dendritic growth signified by 
uniform, dense coverage throughout the entire base area. (b) Highly branched and highly 
extending growth characteristic of a well-fabricated dendritic sample. (c) Poorly 
fabricated dendrite structure with non-uniform growth; dense growth is concentrated to 
the outer rim of the area, with sparse growth observed in the middle of the base area.  (d) 
Poor growth exhibits limited branching and non-extending, shortened structures.  All 
samples shown are 3D dendrites grown on Au-coated Si pillar base arrays.  SEMs taken 
at 30° tilt. 
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4.3 Dendrites for electrochemical sensing  
Electrochemical measurements with dendritic arrays were performed using a three-
electrode system (Fig. 4.3.1a).  The dendritic array functioned as the WE, an external Pt 
wire functioned as the CE, and an external Ag/AgCl electrode served as the reference 
electrode (RE).  Differential pulse voltammetry (DPV) was chosen as the method for 
electrochemical analysis due to its suppression of background current and high 
sensitivity19.  A typical DPV waveform for the oxidation of the redox species 
ferrocenecarboxylic acid (FCA) is depicted in Figure 4.3.1b.  Potential is swept across a 
specified range as a series of pulses and the resultant current is observed.  Ideally, current 
should remain unchanged until a redox reaction occurs, resulting in the peak around 0.3 
V (as observed in Figure 4.3.1b) which is the characteristic potential of FCA oxidation. 
By convention, an oxidation reaction at the WE produces an anodic current and the 
current is therefore designated negative.  Conversely, a reduction reaction produces a 
positively denoted cathodic current.  In the following studies, DPV was performed with 
previously optimized parameters: a pulse size of 50 mV, a pulse time of 0.05 s, a step size 
of 2 mV, and a sample period of 0.1 s.  Potential range varied depending on the redox 
reporter molecule used in order to encompass the oxidation potential of the molecule.       
 
DPVs were performed on dendritic arrays with 1 mM FCA to ensure electrochemical 
integrity of the devices prior to biosensing applications.  Arrays were set up in the 3-
electrode system described in Figure 4.3.1, and 1 mM FCA in PBS, pH 7.4 was placed in 
the well along with the external RE and CE.  All arrays had the same base area of ~12.5 
mm2 (r = 2 mm).  DPVs were performed with a potential range of 0.0 and 0.5 V to 
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encompass the oxidation potential of FCA at 0.3 V.  DPV signals for planar dendrites and 
3D dendrites are shown in Figure 4.3.2, along with their planar Au and Au pillar array 
counterparts.  Peak current was determined for each DPV signal by subtracting the 
current at 0.1 V from the current at 0.3 V.  The planar Au control exhibited a peak current 
of approximately -50 µA while planar dendrites of the same base area exhibited a peak 
current of approximately -20 µA (Fig. 4.3.2a).  Other planar Au samples tested 
demonstrated the same peak current, whereas planar dendrite samples exhibited peak 
currents ranging from -20 to -30 µA.  In addition to a lower peak current, planar dendrites 
tended to exhibit less defined, wider peaks compared to their Au planar counterparts.  
However, the overall current magnitude of the planar dendrites significantly increased 
over the planar Au control.  The planar Au baseline current hovered around -1 µA 
whereas the planar dendrite exhibited a baseline current around -52 µA.  Additionally, the 
planar Au control had a current maximum of -50 µA (same as the peak current), whereas 
the planar dendrites displayed a current maximum of about -75 µA.   
 
The 3D dendrites displayed a similar trend, as seen in Figure 4.3.2b.  Peak currents were 
determined in the same manner by subtracting the current at 0.1 V from the current at 0.3 
V.  The Au pillar control exhibited a peak current of approximately -50 µA while 3D 
dendrites of the same base area exhibited a peak current of approximately -15 µA.  Other 
tested samples exhibited similar peak currents for Au pillar arrays, whereas 3D dendrite 
samples exhibited a peak current range of -15 to -25 µA.  3D dendrites exhibited much 
less defined peaks compared to the planar dendrites as well as the Au pillar array 
counterpart; the peaks appeared characteristically flattened and widened, with a more 
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gradual rise to the current peak.  Furthermore, the overall current magnitude of the 3D 
dendrites was significantly increased over the Au pillar control.  The Au pillar array 
exhibited a baseline current around -1 µA whereas the 3D dendrites exhibited a baseline 
current around -58 µA.  Additionally, the Au pillar control had a current maximum of -50 
µA (same as the peak current), whereas the 3D dendrites displayed a current maximum of 
about -72 µA.  This would suggest that the high current magnitudes observed with planar 
dendritic and 3D dendritic samples may be a result of the increased surface area.  
    
Despite an observed increase in surface area in planar and 3D dendritic samples (as 
confirmed via SEM), electrochemical response to FCA oxidation (as measured by peak 
current) decreased when compared to their control counterparts.  Planar Au and Au pillar 
arrays exhibited peak currents of approximately -50 µA; planar dendrites and 3D 
dendrites displayed peak currents of about -20 µA and -15 µA, respectively.  One may 
expect an increase in surface area to correspond to an increase in electrochemical 
detection of FCA oxidation.  However, the effective surface area that participates in 
electrochemical reactions may be inhibited due to diffusion limitations.  FCA may not be 
able to diffuse into the lower areas of dendritic structures due to their large, complex and 
densely-packed nature.  Therefore, only the top portion of dendritic structures may be 
participating in the oxidation of newly diffusing FCA from the bulk solution.  
 
Furthermore, the concentrated electric fields that occur at points and edges could produce 
high electric fields at the branching ends of dendrites.  This variation in electric field 
throughout the dendrite structure could potentially cause FCA to start oxidizing at earlier 
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potentials (before 0.3 V), specifically at the high electric fields at the point of branches. 
This factor, along with diffusion limitations, could account for the gradual rise of current 
as FCA begins to oxidize at earlier potentials, resulting in the observed flattened, broad 
peak at 0.3 V instead of the sharp well-defined current seen in the control samples.  The 
absence of this broadened FCA peak in other nanostructures, such as the nanocoax, 
further corroborates that this is a structurally-dependent artifact. 
 
The high baseline current and peak current values reported above were present in the 
DPV signals (1 mM FCA) of all dendritic samples (planar and 3D) we have fabricated.  
Currently, we surmise that these characteristics are a product of diffusion limitations, 
increased surface area, and/or the presence of a non-uniform electric field.  While this is 
purely speculation at this point, these DPV curves of FCA oxidation can be used to 
confirm the presence of dendritic growth after DENA and is currently used as an 
electrochemical checkpoint prior to biological sensing.    
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Figure 4.3.1. Electrochemical setup. (a) A three-electrode system was used: the dendritic 
array served as the WE, an external Pt wire served as the CE, and an external Ag/AgCl 
wire functioned as the reference electrode (RE). (b) Typical DPV waveform during the 
oxidation of 1 mM FCA.  X-axis: potential (V); y-axis: current (I).  
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Figure 4.3.2. DPV signals of FCA oxidation on dendritic arrays.  (a) DPV signal for the 
oxidation of FCA on planar dendrites (black) and on a planar Au control (red) of 
corresponding base area.  (b) DPV signal for the oxidation of FCA on a 3D dendritic 
array (black) as well as on a Au pillar control array (red) of corresponding base area. X-
axis: potential (V); y-axis: current (I).   
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4.4 Dendritic-based electrochemical sensors for biosensing 
To demonstrate proof-of-concept for a dendritic-based electrochemical ELISA, an 
alkaline phosphatase (ALP) dose titration was performed and DPVs were recorded on 
planar dendrites.  Serial dilutions of ALP were incubated with 1 mM of the enzymatic 
substrate p-aminophenyl phosphate (pAPP) and then electrochemically examined on 
planar dendrites (Fig. 4.4.1a), as well as on a planar Au electrode to observe whether the 
dendritic architecture affected ALP detection (Fig. 4.4.1b). Each set of titration data 
(planar dendrites and Au planar control) was taken on a single device.  With the planar 
gold device, an ALP concentration of 10-2 ng/ml was required to measure an appreciable 
signal change from baseline at the -100 mV region.  The planar dendrites exhibited a 
noticeable current peak starting at the lowest ALP concentration tested, 10-3 ng/ml.   
 
To determine the range of detection, peak current (Ip) was determined from the DPV 
signals in Figure 4.4.1 and plotted against ALP concentration (shown in Fig. 4.4.2).  The 
planar Au control (black) exhibited lower overall current magnitude compared to the 
planar dendrites (red).  In addition, the planar dendrites detected ALP over all of the 
concentrations tested: 10-3 to 10 ng/ml.  The planar Au counterpart detected ALP over  
10-2 to 10 ng/ml, yet appears to be trending towards upper end saturation at 1 ng/ml.  It is 
worth noting that a 10-3 ng/ml ALP concentration was not tested for planar Au due to an 
electrical short during the DPV measurement; however, the peak current for planar Au at 
10-2 ng/ml ALP appears at a near zero value and is trending to a lower limit of detection.  
On the other hand, the planar dendrites exhibit a peak current still above 1 µA at the 
lowest ALP concentration tested, 10-3 ng/ml.  Therefore, this ALP titration indicated that 
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the dendritic architecture was advantageous in electrochemical detection capabilities, and 
provided proof-of-concept for an electrochemical ELISA on dendritic arrays. 
 
We next developed an electrochemical ELISA for the detection of cholera toxin (CT) as 
previously described in Chapter 3.  The CT ELISA was optimized identically for both 
optical and electrochemical readouts.  All steps were performed in the same manner, 
except in the final step where the reporter molecule was added; Bluephos was added for 
optical readout whereas pAPP was added for electrochemical readout.  EDTA was 
chosen as the stop solution to quench the ALP reaction due to its ability to quench both 
optical and electrochemical ELISAs without interfering in the readout; other stop 
solutions examined, such as sodium hydroxide, interfered with electrochemical readout. 
     
ELISA reactions were performed externally in a 96-well plate and completed assay 
supernatants were then applied to the dendritic array for DPV measurements.  The ELISA 
was run in duplicate and DPVs were recorded separately for the first replicate (R1) 
followed by the second replicate (R2). CT ELISA was performed on planar dendrites and 
on a planar Au control; the resulting DPV signals from one replicate are shown in Figure 
4.4.3.  CT concentrations ranging from 10-2 to 100 µg/ml were examined.  DPV signals 
were subtracted to zero at -0.25 V in order to determine peak current.  The planar 
dendrites (Fig. 4.4.3a) exhibited a higher overall current magnitude compared to the 
planar Au control (Fig. 4.4.3b).  However for both the planar Au and the planar dendrites, 
the lowest tested CT concentration of 10-2 µg/ml produced a distinguishable peak current 
from the “No CT” control baseline. 
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Figure 4.4.1. DPV signal of an ALP dose titration on (a) planar dendrites and (b) planar 
Au.  Current was baselined to zero at -0.25 V to evaluate peak current.  X-axis: potential 
(V); y-axis: current (I).  
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Figure 4.4.2. Detection range of an ALP titration by planar dendrites (red) and planar Au 
control (black).  On the y-axis, peak current (Ip) was plotted against the log-scale of ALP 
concentration (x-axis).  Peak current was determined from DPV signals in Figure 4.4.1.  
Data represent one trial each.   
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CT ELISAs were also performed on 3D dendrites and on a Au pillar control; the recorded 
DPV signals are shown in Figure 4.4.4.  CT concentrations ranging from 10-2 to 100 
µg/ml were examined, and DPV signal was baselined at -0.2 V to elucidate peak current.  
The 3D dendrites (Fig. 4.4.4a) exhibited an overall increase in current magnitude 
compared to the Au pillar control (Fig. 4.4.4b), yet both samples produced noticeable 
current peaks from the “No CT” baseline at the lowest CT concentration tested, 10-2 
µg/ml.  The DPV signals suggest that the Au pillar array appears to be trending toward 
saturation at the upper end, whereas the 3D dendrites can still detect higher CT 
concentrations.    
 
Only the first replicates of each ELISA are shown in Figure 4.4.3 and Figure 4.4.4 and 
are used in the following data analysis for dynamic range determination; this was due to 
significant degradation of 4-AP (the final redox product of the ELISA) observed in the 
second replicates due to prolonged wait time before DPV measurements.  A complete 
disappearance of DPV peaks at lower concentrations was observed in the second replicate 
of the planar Au control, indicating that the effect was not dendritic specific and likely 
due to 4-AP degradation. Therefore, the following ELISAs were performed in staggered 
duplicates to eliminate the discrepancy in wait time between R1 and R2.   
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Figure 4.4.3. DPV signals of CT ELISA on (a) planar dendrites and (b) planar Au.  
DPVs represent the first replicate of an ELISA run in duplicate.  Current was subtracted 
to zero at -0.25 V to determine peak current.  X-axis: potential (V); y-axis: current (I). 
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Figure 4.4.4. DPV signals of CT ELISA on (a) 3D dendrites and (b) Au pillars. DPVs 
represent the first replicate of an ELISA run in duplicate.  Current was subtracted to zero 
at -0.2 V to determine peak current.  X-axis: potential (V); y-axis: current (I). 
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To determine the dynamic range of the tested sensor arrays, peak current was plotted 
against the CT concentration on the log scale (Fig. 4.4.5).  Peak current was determined 
from DPV signals in Figure 4.4.3 and Figure 4.4.4 that were baselined at either -0.25 V 
or -0.2 V, respectively.  Planar Au (purple) and Au pillar (blue) controls exhibited 
overlapping peak current magnitudes and an identical range of detection.  Both controls 
detected CT over a range of 10-2 to 1 µg/ml, with a log-linear region between 10-1 to 1 
µg/ml (R2 ≥ 0.95); however, the curves begin to trend toward a lower end limit at 10-1 
µg/ml.  Planar dendrites (red) exhibited the same range of detection of 10-2 to 1 µg/ml as 
well as the same log-linear region between 10-1 to 1 µg/ml (R2 ≥ 0.95).  However, the 
overall magnitude of the peak current was increased by approximately 10-fold over the 
Au planar control.  3D dendrites (black) had an improved range of detection over the 
controls and the planar dendrites.  3D dendrites were capable of CT detection over all 
concentrations tested: 10-2 to 100 µg/ml.  Although the 3D dendrites do not exhibit tight 
log-linearity with this one replicate, they maintain a somewhat linear trend and have not 
yet reached a lower or upper limit.   
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Figure 4.4.5. Detection range of CT ELISA on planar dendrites (red) and 3D dendrites 
(black).  Planar Au (purple) and Au pillar (blue) controls were also examined.  On the y-
axis, peak current (Ip) was plotted against the log-scale of CT concentration (x-axis).  
Peak current was determined from baselined DPV signals from Figures 4.4.3 and 4.4.4.  
Data represent one trial each.    
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In addition, the electrochemical ELISA readout on dendritic arrays was compared to the 
conventional optical ELISA as a standard control.  The optical ELISA was performed in 
the same manner as the electrochemical ELISA, with the exception that the BluePhos 
substrate was used in place of pAPP.  BluePhos is converted by ALP into a colorimetric 
product, whose optical absorbance is read at λmax=600 nm.  In Figure 4.4.6, CT 
concentration was plotted against absorbance; the optical readout exhibited a log-linear 
range of detection from 10-2 to 1 µg/ml CT (R2 ≥ 0.95).  Additionally, the optical ELISA 
does not appear to be reaching a lower limit of detection.   
 
3D dendrites exhibited improved electrochemical detection of CT over the other 
electrochemical sensing devices tested (Table 4.4.1).  3D dendrites detected CT over a 
range of 10-2 to 100 µg/ml while its Au pillar array counterpart, planar dendrites, and 
planar Au detected CT over a range of 10-2 to 1 µg/ml.  Additionally, 3D dendrites 
electrochemical readout increased the upper range of detection when compared to the 
optical ELISA, which exhibited a detection range of 10-2 to 1 µg/ml.  This suggested that 
the 3D dendritic architecture may have the potential to improve sensitivity and extend the 
dynamic range of CT detection over planar dendrites and non-dendritic counterparts, as 
well as the standard optical ELISA.  Although only one replicate was analyzed, the 
results suggested improved electrochemical sensing with 3D dendrites over the planar 
dendrites.  Therefore, 3D dendritic arrays were the chosen architecture with which to 
progress development and characterization as an electrochemical biosensor.  Following 
studies increased CT concentrations beyond the 10 ng/ml lower limit to discover the true 
LOD and range of detection; the lower end had not yet trended to a zero value in either 
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the electrochemical and optical readouts, suggesting that both methods are capable of CT 
detection beyond the range of CT investigated.  Moreover, ELISA replicates were 
staggered to prevent degradation of 4-AP.    
 
Staggered ELISA reactions were performed externally in a 96-well plate and completed 
assay supernatants were then applied to the dendritic array.  The ELISA was run in 
duplicate with staggered replicates.  All steps of the ELISA were run in parallel in both 
replicates until the final step: addition of 1 mM pAPP.  1 mM pAPP in TBS, pH 9 was 
added to the first replicate (R1), while TBST, pH 7.4 was added to the second replicate 
(R2).  The ELISA proceeded to completion in R1, and DPVs were immediately recorded 
for R1.  Buffer was then removed from R2 and 1 mM pAPP in TBS, pH 9 was added to 
complete the assay.  DPVs were then subsequently recorded for R2 on the same device.   
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Figure 4.4.6. Detection range of optical CT ELISA.  On the y-axis, absorbance at 600 nm 
is plotted against the log-scale of CT concentration (x-axis). Data represent two trials.  
Error bars represent standard deviation.  
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Table 4.4.1. Upper and lower limits of a CT ELISA for various detection methods. 
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CT ELISAs were performed in the aforementioned staggered manner on 3D dendrites, a 
Au pillar control array, and a planar Au control.  The resulting DPV signals from one 
replicate are shown in Figure 4.4.7.  DPV signals were subtracted to zero at -0.2 V in 
order to determine peak current.  The planar Au and Au pillar array controls (Fig. 4.4.7a 
and Fig 4.4.7b, respectively) exhibited similar overall current magnitudes, whereas the 
3D dendrites demonstrated a significant increase in overall current magnitude (Fig 
4.4.7c).  
 
To determine the dynamic range, peak current was plotted against CT concentration in 
Figure 4.4.8.  Peak current was determined from baselined DPV signals in Figure 4.4.7.  
3D dendrites (black) exhibited an increase in current magnitude over the planar Au (red) 
and Au pillar array (blue), with an approximate 4-fold increase in current at each CT 
concentration.  3D dendrites exhibited a log-linear range of detection over 10-2 to 10-1 
µg/ml (R2 ≥ 0.95), and the Au pillar array and planar Au both had a log-linear range of 
detection from 2x10-2 to 10-1 µg/ml (R2 ≥ 0.95).  All three detection platforms reached 
upper end saturation at 10-1 µg/ml.  3D dendrites exhibited a lower limit of 2x10-3 µg/ml; 
however Au pillar arrays and planar Au were not examined for CT concentrations lower 
than 2x10-3 µg/ml and 10-2 µg/ml, respectively, and so their true LOD could not be 
determined.  This was due to the fact that a proper CT concentration range for ELISAs 
was still being investigated.      
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Figure 4.4.7. DPVs of a staggered CT ELISA on (a) planar Au, (b) Au pillars, and (c) 3D 
dendrites.  DPV signals were subtracted to zero at -0.2 V to elucidate peak current. X-
axis: potential (V); y-axis: current (I) 
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Figure 4.4.8. Detection range of a staggered CT ELISA on 3D dendrites (black).  Planar 
Au (red) and Au pillar (blue) controls were also examined.  On the y-axis, peak current 
(Ip) was plotted against the log-scale of CT concentration (x-axis).  Peak current was 
determined from baselined DPV signals from Figure 4.4.7.  Dashed lines represent 
background current (“No CT” control current value) for 3D dendrites (black line) and Au 
planar and Au pillars (red line).  Data represent two trials run on the same device.  Error 
bar shown is standard deviation.    
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A difference in the DPV baselines was observed between dendritic samples and the 
control counterparts.  In the planar Au and Au pillar control sensors, the “No CT” 
background current in the baselined DPVs was approximately 0 µA at the oxidation 
potential of 4-AP (-0.1 V).  This can be seen by the lack of an appreciable slope in the 
“No CT” DPV signal (Fig. 4.4.7a and Fig. 4.4.7b) as well as quantitatively by the dashed 
line (red) in Figure 4.4.8.  On the other hand, the “No CT” background current in the 
baselined DPV in dendritic sensors has a non-zero value at -0.1 V.  The DPV signals in 
the dendritic samples slope downward, giving the control and background signals (i.e. CT 
concentrations that do not change from the “No CT” control) an assigned, non-zero 
current value.  This slope can be seen in the “No CT” DPV signal in Figure 4.4.7c; the 
non-zero background current can be seen quantitatively by the dashed line (black) in 
Figure 4.4.8.   
 
This appearance of a significant downward slope was present in all dendritic-based 
sensors, both planar and 3D.  In an I-V curve such as the DPV, the slope of the curve’s 
baseline corresponds inversely to the resistance of the system.  A negligible slope, as seen 
in the planar Au and Au pillar samples, indicates high resistance and therefore lower 
conductance.  Conversely, the larger slope seen with dendritic DPVs indicates lower 
resistance and therefore higher conductance.  While the origin of this effect is still 
unknown, this could suggest that the additional, nanostructured surface area of the 
dendritic structures increases the conductance of the electrode and reduces the resistance 
of the electrochemical system.    
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4.5 Variations in dendritic structure 
Variation in the detection range of CT by 3D dendrites was observed between the 
previous ELISA (Fig. 4.4.5) and the staggered ELISA (Fig. 4.4.8). The initial 3D 
dendritic array detected CT over a range of 10-2 to 100 µg/ml, while maintaining a linear 
trend over all concentrations detected.  The latter 3D dendritic array exhibited a 
decreased range of detection at the upper end, with a log-linear dynamic range from 10-2 
to 10-1 µg/ml.  To determine the cause of this discrepancy, SEMs of the two different 
samples were examined.  SEM images of the 3D dendritic array from the first CT ELISA 
are shown in Figure 4.5.1.  As seen in Figure 4.5.1a, dendritic growth was not uniform 
across the sample.  The inner region, highlighted by box 1 and magnified in Figure 
4.5.1b, exhibited sparse growth with short, non-extending dendrites.  The outer region, 
designated by box 2 and magnified in Figure 4.5.1c, possesses dense, highly branched 
and highly extending dendrites.   
 
The dendritic array used in the second CT ELISA displayed a different growth pattern 
(Fig. 4.5.2).  In Figure 4.5.2a, the majority of the sample exhibited uniform growth, 
however this growth was limited.  Figure 4.5.2b highlights the dendritic growth 
characteristic of the majority of the sample (box 1 in Fig. 4.5.2a); the dendrites are 
similar the inner region of the initial array, with sparse coverage and stubby, non-
extending structures.  The desired dense, highly-branched and highly-extending dendritic 
structures are only observed in a thin outer region, highlighted by box 2 in Figure 4.5.2a 
and magnified in Figure 4.5.2c.   
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The structural variance between these two samples may account for the discrepancy in 
detection range of CT.  The first dendritic array demonstrated a greater range of 
detection, as well as a larger portion of the sample (≥ 50%) covered with highly-
branched, extending dendritic structures.  Conversely, the second dendritic array was 
dominated with sparse, limited dendritic growth and a decreased range of detection was 
observed.  These results supported that the idea that increased, expansive dendritic 
growth is capable of increasing electrochemical detection.  Several subsequent dendritic 
samples (n = 3) were fabricated in an attempt to reproduce the initial dendritic structure, 
however variations still existed between these samples and they more closely resembled 
the second, sparsely-coated dendritic array. It was apparent that proper dendritic 
fabrication was not reproducible between samples at this point; therefore, DENA 
parameters were examined to reproducibly and repeatedly produce samples with uniform 
coverage of extensive dendritic growth. 
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Figure 4.5.1. SEMs of 3D dendritic array used in initial, non-staggered ELISA from 
Figure 4.4.5. (a) SEM of entire sample area.  The inner region highlighted by box 1 is 
magnified in (b).  The outer region highlighted by box 2 is shown in (c).  SEMs taken at 
30° tilt. 
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Figure 4.5.2. SEMs of 3D dendritic array used in staggered CT ELISA from Figure 
4.4.8.  (a) SEM of entire sample area.  The dendritic structure of the majority of the 
sample is highlighted by box 1 and is magnified in (b).  Growth in the thin outer region 
highlighted by box 2 is shown in (c).  SEMs taken at 30° tilt. 
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4.6 Optimization of DENA growth parameters 
Several DENA parameters were investigated and the resulting dendritic arrays were 
examined via SEM (Figure 4.6.1).  Previously, DENA had been performed using a square 
waveform with the following standard parameters: a frequency of 30 MHz, an amplitude 
of 5 Vpp, a potential offset of -1.25 Vo, 50% duty cycle and 0 phase for 20 min in 30 mM 
HAuCl4, with a WE-CE distance of 100 µm.  The parameters examined included HAuCl4 
solution temperature, WE-CE electrode distance, and frequency.   
 
In Figure 4.6.1a, DENA was performed with the standard parameters, however the salt 
solution was allowed to warm fully to room temperature (10 min) prior to dendritic 
growth.  The salt solution is stored in 4°C, and had previously been used for DENA 
immediately after removal from the fridge.  Under this condition, not only was uniform 
coverage achieved, but the dendritic growth was highly-branched and extensive across 
the entire sample.  A control array was grown with the standard conditions and no salt 
solution warm up time (Fig. 4.6.1b); the solution was applied directly to the array for 
DENA from the fridge.  No warm up time resulted in a dendritic array that had limited 
growth in comparison to the array with 10 min warm up.  The left panel in Figure 4.6.1b 
indicates a reduced growth in comparison to the array in the left panel of Figure 4.6.1a.  
Additionally, the magnified right panel of Figure 4.6.1b displays shortened dendritic 
structures that are lacking the highly-branched character observed in the right panel of 
Figure 4.6.1a.  These results indicated that the 10 min warm up time is critical, and may 
allow for improved diffusion of gold salt ions to the electrode surface during DENA.  All 
following DENA processes were carried out with a 10 min warm up time. 
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Electrode distance between the WE and CE was also examined, as it was thought that a 
greater WE-CE distance may improve electric field uniformity and therefore dendritic 
growth.  In Figure 4.6.1c, the WE-CE distance had been increased from the standard 100 
µm to 5 mm, and DENA was performed after the salt solution had reached room 
temperature.  While the growth coverage appeared uniform across the sample (as seen in 
the left panel of Fig. 4.6.1c), the dendritic structure was shortened and did not display 
elongated branching (right panel Fig. 4.6.1c).  Therefore, this suggests that the standard 
100 µm is the more optimal WE-CE distance for fabricating the desired, highly extensive 
dendrites. 
 
Frequency of the DENA square waveform was also tested.  It had previously been 
demonstrated that increased DENA frequency results in decreased nanowire radius and 
increased growth tip velocity11; therefore, we hypothesized that increasing the frequency 
may allow for thinner, taller structures.  In Figure 4.6.1d, the frequency was increased 
form the standard 30 MHz to 50 MHz, and DENA was performed after the salt solution 
had reached room temp.  Uniform coverage was obtained (left panel Fig. 4.6.1d) however 
growth appeared limited when compared to growth observed in Figure 4.6.1a.  Upon 
magnification (right panel Fig. 4.6.1d), it was observed that the increased frequency did 
not improve dendrite growth over the standard 30 MHz frequency; dendrites were short 
and stubby, and lacked branching.  Therefore, the standard frequency of 30 MHz was 
maintained in following DENA growth processes. 
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After reproducible fabrication of dendritic structures was achieved, electrochemical 
biosensing studies were resumed.  In the following studies, dendrites were fabricated on 
photolithographically-patterned chips using a new macroscale set-up.  DENA processes 
were performed with a frequency of 30 MHz, an amplitude of 5 Vpp, an offset of -1.25 
Vo, a phase of 0, and a duty cycle of 50% for 20 min with a WE-CE distance of 100 µm.  
The solution concentration was kept at 30 mM HAuCl4, however underwent a 10 min 
warm-up period prior to DENA processes.  While further studies into optimizing DENA 
parameters should be investigated in the future, we continued to examine electrochemical 
sensing abilities of uniformly covered, extensively-branched dendritic samples to 
determine whether the dendritic architecture offered any advantage over the standard 
ELISA.        
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Figure 4.6.1. SEMs of 3D dendritic arrays with varied growth parameters.  
 
150 
 
Figure 4.6.1. SEMs of 3D dendritic arrays with varied growth parameters. (a) Dendritic 
array grown under standard conditions with a 10 min warm up for the 30 mM HAuCl4 
solution prior to DENA. (b) Control array grown under standard conditions and with no 
solution warm up time.  DENA was performed with solution from 4°C storage.  (c) 
Dendritic array grown with a distance of 5 mm between the WE and CE instead of the 
standard 100 µm WE-CE distance.  A 10 min warm up for the 30 mM HAuCl4 was 
included; all other parameters were standard.  (d) Dendritic array fabricated with a 50 
MHz frequency instead of the standard 30 MHz.  A 10 min warm up for the 30 mM 
HAuCl4 was included; all other parameters were standard.  SEMs taken at 30° tilt.   
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4.7 Fabrication of dendritic arrays on photolithograpically-patterned chips 
Following DENA procedures were performed on a new macroscale setup, as previously 
described in Section 4.2. Using this setup, the substrate was placed directly into the salt 
solution, eliminating the requirement for a well reservoir during DENA.  In this manner, 
samples could be imaged via SEM to ensure proper growth prior to use for 
electrochemical ELISA measurements. Additionally, a photolithographically-patterned 
chip was designed in order to permit growth only in certain designated areas, as opposed 
to over the entire submersed chip.  This would allow for several individually-addressed 
arrays on a single chip, which would be amenable for future biomarker multiplexing and 
biofunctionalization.  As seen in Figure 4.7.1a, the chips consisted of eight, individually-
addressed, Au pillar array regions, each with a base area of ~3 mm2.  The area outside of 
these regions was protected by photoresist, including the gold leads, to prevent dendritic 
growth during DENA. Gold pads were exposed (i.e. not covered in photoresist) in order 
to connect the arrays to the circuit for DENA growth.  These gold pads remained outside 
of the salt solution, protected from DENA processes as seen in Figure 4.7.1b.  The chip 
was designed with the future prospect of simultaneously growing dendrites on all eight 
regions, to ideally grow structurally identical dendritic arrays.  These arrays could be 
biofunctionalized with ELISA antibodies to move away from the plate-based format 
towards a more POC prototype, as well as provide a miniaturized platform for 
multiplexing.        
 
3D dendrites were grown with the macro-scale setup on one array of the patterned chip.  
The DENA parameters previously stated in section 4.6 were used; however in these 
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macro-scale studies, the WE-CE distance was ~25 mm and either a coiled Pt wire or 
planar Au chip were used as the CE depending on availability.  SEM images confirmed 
proper growth, designated by uniform coverage of extensively branched dendritic 
structures across the sample.  The SEM image in Figure 4.7.2a shows the overall region 
of the dendritic array.  The majority of the array exhibited consistent coverage of 
dendritic structures ranging from tens to hundreds of microns in length (Figure 4.7.2b), 
except for a portion of the array on the left outer region.  In this area, dendritic growth 
appeared denser and more extensive as seen in Figure 4.7.2c.  This effect is also noted to 
a lesser degree around the entire circumference of the array.  This is likely due to 
accelerated growth at the edge where the electric field is strongest, as well as unhindered 
access to the HAuCl4 solution; inner regions of the area may be diffusion limited and 
competing for reagent, whereas the outer region has no other growing dendritic branches 
with which to share reagent or compete, allowing these outer branches to grow without 
any steric limitations.   
 
Using the DENA macroscale setup, a 3D dendritic array was fabricated that was 
consistent with the desired growth previously acquired with the micro-scale setup.  
Dendritic structures were highly branched and extensive, while maintaining uniform and 
consistent coverage across a majority of the sample.  Additionally, the targeted array was 
the only array that exhibited any dendritic growth despite all arrays being submerged in 
the solution.  This indicated that the arrays were independently addressed and that the 
gold leads were properly protected by the photoresist.  Using this photolithographically-
patterned chip, multiple electrically-isolated arrays can be grown simultaneously on a 
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single chip, providing a platform amenable to multiplexing and a potential on-chip 
ELISA format in the future.  Additionally, this chip allows for SEM examination and 
confirmation of dendritic growth prior to electrochemical measurements, unfeasible 
before with the micro-scale setup.  
 
 
 
 
 
 
 
 
 
 
 
154 
 
 
Figure 4.7.1. Photolithographically-patterned chips for 3D dendritic arrays. (a) Patterned 
chip containing eight, individually addressed, Au pillar arrays of base area ~3 mm2 each. 
Gold leads connect each array to a respective gold pad.  The gold leads are protected by 
photoresist; the arrays and pads remain exposed for either dendritic growth or connection 
to the circuit, respectively.  Dimensions of entire chip area are 16 x 30 mm2.  (b) 
Patterned chip in the macro-scale setup for DENA.  Exposed Au pillar arrays are 
submerged in 30 mM HAuCl4; the gold pad corresponding to the array targeted for 
DENA growth is connected by an alligator clip to the circuit.   
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Figure 4.7.2. SEMs of a 3D dendritic array on a photolithographically-patterned chip. (a) 
Entire region of dendritic array with base area ~3 mm2. (b) Dendritic growth 
characteristic of inner region as well as the majority of the sample. (c) Dendritic growth 
characteristic of the outer left region of the array, as well as dendrites lining the 
circumference of the array.  SEMs taken at 30° tilt. 
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4.8 Dendritic-based biosensors using photolithographically-patterned arrays 
After SEM confirmation of proper dendritic growth on photolithographically-patterned 
chips, well reservoirs were attached around each array (as previously described in Section 
2.5.1) and electrochemical ELISAs were performed.  CT concentration range was 
expanded from previous ELISAs in order to determine the true dynamic range and LOD 
of dendritic-based sensors.  ELISAs were performed in duplicate and both replicates were 
electrochemically measured concurrently on the same device.  Identical CT 
concentrations in both replicates were measured in parallel as opposed to measuring all of 
R1 first and then R2 as was done with a staggered ELISA.  Degradation effects of 4-AP 
between replicates were significantly minimized in this manner.  In addition, any 
variation in the addition of pAPP to R1 and R2 in staggered stages was eliminated.   
 
DPV signals of a CT ELISA were recorded with a 3D dendritic array (Fig. 4.8.1a), as 
well as with a Au pillar control array (Fig. 4.8.1b).  CT concentrations ranging from 10-4 
to 10 µg/ml were examined.  DPV signals were baselined to zero at -0.2 V in order to 
determine the peak current in the -0.1 V region.  With the Au pillar control, a CT 
concentration of 10-2 µg/ml was required in order to measure an appreciable signal 
change from baseline.  However, the 3D dendritic array exhibited a noticeable peak 
current from baseline starting at 2x10-3 µg/ml CT.  
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Figure 4.8.1. DPVs of CT ELISA on a photolithographically-patterned chip containing 
(a) 3D dendritic array and (b) a control Au pillar array.  DPV signals were subtracted to 
zero at -0.2 V to determine peak current.  Data represent one replicate of CT ELISAs run 
in duplicate.  X-axis: potential (V); y-axis: current (I).     
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To determine the dynamic range, peak current was plotted against the CT concentration 
on the log scale in Figure 4.8.2.  Peak currents (Ip) were determined from baselined DPV 
signals in Figure 4.8.1.  Dashed lines correspond to the average current value of the “No 
CT” control and lower CT concentrations that did not produce a peak current from 
baseline.  The Au pillar array control (blue) exhibited a lower overall current magnitude 
compared to the 3D dendritic array (black).  Additionally, the 3D dendritic array 
demonstrated a greater log-linear dynamic range, over the CT concentrations of 2x10-3 to 
10-1 µg/ml (R2 ≥ 0.95).  The Au pillar control, on the other hand, exhibited a log-linear 
dynamic range over the concentrations of 10-2 to 10-1 µg/ml CT (R2 ≥ 0.95).  The 
dendritic architecture increased the sensitivity of the detection by an order of magnitude, 
improving the pillar array LOD from 10-2 to 10-3 µg/ml with the dendritic array.    
 
Here, we observed the sloping DPV baseline associated with previous dendritic samples 
in the 3D dendritic array on the photolithographically-patterned chip.  The Au pillar array 
produced a relatively non-sloping baseline as seen in previous control samples.  Dendritic 
samples on the patterned chip maintained the low resistance and high conductance seen 
with prior dendritic samples fabricated with the micro-scale setup. Additionally, the 3D 
dendritic array on the patterned chip improved the lower end detection range of CT by an 
order of magnitude over 3D dendrites fabricated in the micro-scale setup.  Initial CT 
ELISAs on micro-scale fabricated 3D dendrites exhibited a log-linear range of detection 
of 10-2 to 100 µg/ml CT.  On the other hand, the patterned 3D dendritic array detected CT 
over a log-linear range of 2x10-3 to 10-1 µg/ml.  This could be due to the smaller dendritic 
footprint in the overall area contained by the well reservoir on the patterned chip; the 
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dendritic array has a base area of 3 mm2 but the well reservoir encapsulates an area of 
~12.5 mm2.  Therefore, there is extra room around the array in which reagent can diffuse 
to the sides of the outer edge dendrites on the array circumference.  This property may 
allow for improved diffusion of redox reporter to the outer side portion of the array, 
increasing the lower end level of detection.  In the previous set-up, however, the entire 
area encapsulated by the well reservoir was covered with dendritic growth (~12.5 mm2), 
limiting reagent diffusion to the top of the array only.  Further studies should be 
conducted in which pillar spacing is increased to find the ideal “sweet spot”, where 
reagent is free to diffuse around each dendrite and is not hindered by surrounding 
dendritic growth, yet the advantage of increased surface area is maintained.  
 
Electrochemical detection with the 3D dendritic sensor was compared to the conventional 
optical ELISA as a standard control.  The optical ELISA was carried out in duplicate and 
the results are shown in Figure 4.8.3, with absorbance plotted against CT concentration.  
The dashed line corresponds to the average absorbance value of the “No CT” control.  
The optical readout was log-linear over a dynamic range of 10-3 to 10-1 µg/ml (R2 ≥ 0.95), 
with a LOD of 10-3 µg/ml.  Electrochemical detection was log-linear over the dynamic 
range of 2x10-3 to 10-1 µg/ml (R2 ≥ 0.95) and exhibited a similar LOD of 2x10-3 µg/ml. 
These results indicated that the dendritic electrochemical sensor is comparable to the 
standard optical ELISA, exhibiting a log-linear dynamic range of detection over the same 
2 orders of magnitude (10-3 to 10-1 µg/ml) and a LOD on the same order of magnitude 
(10-3 µg/ml). 
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Figure 4.8.2. Detection range of CT ELISA on photolithographically-patterned 3D 
dendritic array (black).  A control Au pillar array (blue) on the same chip was also 
examined.  On the y-axis, peak current (Ip) was plotted against the log-scale of CT 
concentration (x-axis).  Peak current was determined from baselined DPV signals from 
Figure 4.8.1.  Dashed lines correspond to the average current of the “No CT” and lower 
CT concentrations that did not produce a peak current.  Data represent two trials run on 
the same device.  Error bar shown is standard deviation.    
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Figure 4.8.3.  Detection range of optical CT ELISA.  On the y-axis, absorbance at 600 
nm is plotted against the log-scale of CT concentration (x-axis). Dashed red line 
corresponds to average absorbance value of the “No CT” control.  Data represent two 
trials.  Error bar represent standard deviation. 
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4.9 Future directions: biofunctionalization and dendritic ECC sensors   
We have demonstrated dendritic electrochemical detection of cholera toxin (CT) with 
sensitivity comparable to the conventional optical readout.  However, to be further 
developed into a POC device, ELISA antibodies must be conjugated to the dendritic 
surface in order to move away from the plate-based format towards a portable device.  
Conjugation of antibody directly to the electrode surface would eliminate diffusion 
limitations previously observed.  Pillar spacing could also be adjusted to a greater pitch 
(i.e. more space between pillars) to additionally aid in overcoming diffusion issues.  
Several biofuncationalization strategies have been assessed and characterized for the 
conjugation of protein to planar gold as well as Au pillar arrays.  In the future, these 
protocols will be applied to functionalizing 3D dendritic arrays with antibodies to 
produce a dendritic, on-chip electrochemical ELISA.   
 
We have recently utilized DENA to grow dendritic structures onto nanocoaxial structures 
in an attempt to increase electrochemical detection sensitivity.  Extended core coaxes 
(ECCs) were prepared as previously described in Section 3.6 and resulting ECC structure 
was verified via SEM (Figure 4.9.1a).  DENA was performed with the macro-scale setup 
on the ECC array, using the inner gold core as the working electrode and an external 
planar Au chip as the counter electrode.  DENA was executed with the same parameters 
as before, except the duration was reduced from 20 min to 30 s to prevent shorting 
between the inner and outer ECC electrodes due to overgrowth.  An SEM image of the 
resulting dendritic ECC is shown in Figure 4.9.1b.  Dendritic structures grew on the 
protruding inner core as well as on the outer chrome electrode; growth on the outer 
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electrode is most likely due to improper grounding of the chrome.  However, high 
resistance measurements (GΩ regime) between the inner and outer electrode indicated 
that there was no shorting and so the dendritic ECC was used for electrochemical 
measurements.      
 
To examine the potential of the dendritic ECC architecture for electrochemical sensing, 
DPVs were performed to detect the oxidation of 1 mM FCA (Fig. 4.9.2).  Multiple DPV 
measurements exhibited similar current signals, with an average peak current of 
approximately -16 µA; peak current was determined by subtracting the current at 0.1 V 
from the current at ~2.8 V where the peak appeared.  Current densities (J) were 
calculated for the dendritic ECC, the ECC, and the first generation nanocoax to compare 
electrochemical performance of the three nanoarchitectures (Fig. 4.9.3); a planar Au 
control was compared as well.  Current densities were determined by dividing peak 
current by array base area.  The dendritic ECC array exhibited a current density of 320 
µA/mm2, whereas the ECC array alone had a current density of 150 µA/mm2 and the 
nanocoaxial array exhibited a current density of 83 µA/mm2.  Planar Au sensors 
produced a current density of 5 µA/mm2.  In this initial study, the dendritic ECC array 
doubled the current density over the standard ECC array, on an array base area 4x 
smaller.   
 
The increased current density of the dendritic ECC array could allow for improved 
sensitivity in the electrochemical detection of biomarkers over the standard ECC array 
alone.  However, more studies must be conducted to corroborate these initial studies.  
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DENA growth times for fabricating dendritic ECCs need to be examined as well as 
fabricating structures with properly grounded outer chrome electrodes.  Once an 
optimized and reproducible dendritic ECC structure has been obtained, further studies 
(ALP dose titrations, ELISAs) with the dendritic ECC arrays will be completed to 
determine if the increased current density corresponds to improved sensitivity.              
165 
 
 
Figure 4.9.1. SEM images of an ECC array (a) before dendritic growth and (b) after 
DENA has been performed (b).  ECCs are composed of an inner Au working electrode 
and an outer Cr counter electrode. Scale bar represents 2 µm. SEMs taken at 30° tilt. 
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Figure 4.9.2. DPV signals of 1 mM FCA on a dendritic ECC array.  DPVs were 
measured on the same device.  X-axis: potential (V); y-axis: current (I). 
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Figure 4.9.3. Current densities (J) of planar Au, nanocoax, ECC, and dendritic ECC 
arrays during the oxidation of 1 mM FCA. Current densities were determined by dividing 
DPV peak current by each array base area.  
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Summary 
Utilizing directed electrochemical nanowire assembly (DENA), dendritic-based 
electrochemical arrays have been fabricated and developed on several base substrates.  
Gold dendrites were fabricated on planar Au and Au pillar arrays to create planar and 3D 
dendritic structures.  These dendritic sensors were tested in their ability to detect CT in an 
electrochemical ELISA.  While planar dendrites exhibited the highest current signal, 3D 
dendrites demonstrated greater range of detection and lower limits of detection.  3D 
dendrites were subsequently chosen for further studies into dendritic-based 
electrochemical sensors.  Following 3D dendritic sensors, however, produced dissimilar 
results due to varying dendritic growth between samples.  Therefore, DENA parameters 
were examined and optimized to allow for reproducible dendritic growth. 
 
3D dendrites were fabricated on photolitographically-patterned chips containing eight 
individually-addressed arrays.  CT ELISAs were then performed on these 3D dendritic 
sensors, which improved detection over its Au pillar array counterpart by an order of 
magnitude.  Additionally, the 3D dendritic array matched the performance of the standard 
optical ELISA with regard to dynamic range of detection and limit of detection.  
Furthermore, these dendritic-based arrays offer advantages over the conventional ELISA.  
The electrochemical readout of the dendritic array does not require the complex 
instrumentation or high amount of reagent needed in the optical readout.  Dendritic arrays 
are also easily amenable to multiplexing for the simultaneous detection of disease 
biomarkers, a highly desired POC option not easily acquired in optical setups.  Finally, in 
the future, the benefit of the close proximity of the nanocoaxial WE–CE distance could 
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be combined with the dendritic advantage of increased surface area by utilizing DENA 
on the inner core of the ECC.  These future studies hold a promising path to a highly 
sensitive and robust POC device for infectious disease detection.    
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Chapter 5. 
Discussion and concluding remarks 
  
173 
 
The standard optical enzyme-linked immunosorbent assay (ELISA) is limited in point-of-
care (POC) applications due to complex instrumentation, high reagent consumption, cost, 
and lack of facile multiplexing capabilities.  The electrochemical readout of an ELISA 
with nanocoaxial arrays and dendritic arrays developed in this thesis was shown to match 
the standard optical ELISA with regards to cholera toxin (CT) detection range and limit 
of detection (LOD), while overcoming a handful of these limitations. These 
nanoarchitectures allow for a simple electrical readout while requiring orders of 
magnitude less reagent.  In addition, these architectures allow for facile multiplexing due 
to the ability to fabricate multiple electrically-independent arrays on a single chip.  
Therefore, these nanostructures offer advantages over the conventional ELISA that make 
them attractive candidates for further development towards POC applications.      
 
Nanocoax 
In these studies, we utilized the nanocoax as a nanogap sensor in order to take advantage 
of the nanoscale proximity of the working electrode (WE) and counter electrode (CE) to 
enhance electrochemical sensitivity.  Recently, increased efforts have been made towards 
the fabrication of nanogap biosensors to allow for large-scale production, easy read-out 
and high sensitivity1.  A sensor with a nanometer-scale electrode gap can bring target 
biomolecules spatially closer to these sensing electrodes, enhancing detection and 
sensitivity2.  The biomolecules can be detected through electrical behaviors such as 
resistance/impedance, capacitance/dielectric response, or field-effect3, allowing for many 
label-free detection schemes based on a change in electrical signal upon biomolecule 
presence or binding.   
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The majority of nanogap biosensor research has been focused on the detection of DNA 
oligonucleotides1,4–7.  Nanogap sensors can be conjugated with a probe oligonucleotide 
sequence that is complimentary to the target DNA strand.  Upon hybridization of the 
target sequence, a change in the electrical signal is induced.  Zaffino et al.8 demonstrated 
label-free detection of single point mutations via DNA hybridization with a conductance-
based nanogap sensor.  Hybridization of complimentary DNA strands resulted in an 
increase in current; however DNA strands with a single base pair mismatch were 
discriminated, resulting in high specificity.  Several studies have recently applied this 
concept to the detection of target protein biomarkers9,10.  For example, Gu et al.11 utilized 
a nanogap field-effect transistor for the electrical detection of the anti-avian influenza 
antibody.   Despite high sensitivity achieved with such sensors, only a small number are 
being further developed towards POC applications due to the high cost and low yield 
associated with current fabrication methods12.        
 
The structure of current nanogap biosensors consists of 2D planar and 3D nonplanar 
architectures, oftentimes in the form of a field-effect transistor.  Many planar nanogap 
biosensors are composed of nanowires arranged horizontally on substrates.  3D nanogap 
sensors are mainly composed of electrodes parallel to each other (either horizontally or 
vertically), increasing the electrode area within the nanoscale proximity over the planar 
nanogap sensors.  Our nanocoax is a 3D nanogap structure that provides an additional 
advantage over most conventional 3D nanogap biosensors.  In the coaxial structure for 
electrochemical detection, the inner WE is circumferentially surrounded by the outer CE, 
as opposed to other 3D nanogap structures that consist primarily of two parallel 
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electrodes.  This concentric outer CE allows for the radial diffusion of molecules from all 
sides whereas most 3D nanogap sensors are limited by linear diffusion in a single 
direction.  As a result, the nanocoax allows for increased redox cycling over the 
conventional parallel electrode setup, and thus an increase in signal.  
 
Furthermore, fabrication of the nanocoax utilizes techniques that are economical and 
reproducible.  The use of nanoimprint lithography provides a reusable, low-cost “master” 
tool to produce well-ordered templates for nanocoaxial arrays.  Additionally, the vast 
majority of the fabrication costs are associated with labor; the actual cost of materials is 
negligible in comparison.  This fabrication technique also has the ability to allow for high 
scalability, which would enable the desired low-cost, high-yield characteristic needed for 
POC device development.  While we did encounter electrical conductivity issues (too low 
resistance, and even shorting) with some batches, the nanocoaxes that displayed high 
resistance (i.e. R ≥ 1 GΩ) and that were used for the electrochemical detection of CT 
exhibited comparable ranges of detection.  This would indicate that properly fabricated 
nanocoaxes are reproducible as electrochemical biosensors, however quality control 
checks and fabrication protocols between batches need to be standardized to improve 
yield. 
   
The next generation coax currently under development, the extended core coax (ECC), 
continues to utilize these fabrication techniques and provides a coaxial architecture more 
amenable to POC applications.  The extended inner core could be functionalized with an 
ELISA antibody against a target infectious disease biomarker in order to move away 
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from the plate-base format to a lab-on-chip assay.  Furthermore, elimination of the 
coaxial WE-CE annulus in the ECC could minimize diffusion issues encountered in the 
first generation coaxes, and would allow for a flow-across device while still maintaining 
the advantageous nanoscale WE-CE proximity.  With this ECC platform, multiplexing 
the electrically-independent nanocoaxial arrays on a single chip would still be feasible, 
allowing for the simultaneous detection of multiple infectious disease biomarkers.  
Previously, array areas as small as 150 µm2 have been fabricated, containing only ~100 
nanocoaxes and requiring only ~10 fl sample volume.  Such a chip could be 
biofuncitonalized with capture antibody and coupled with microfluidics to produce a 
portable, pre-packaged POC device. 
 
Dendrites 
In biosensors lacking the nanoscale WE-CE proximity, an attractive approach to 
enhancing the sensitivity is to increase the number of biomolecular events at the electrode 
surface by increasing the 3D surface area.  The large footprint of 3D nanostructured 
electrodes facilitates high levels of collisions with target analytes and promotes higher 
rates of diffusion13.  Additionally, the increased surface area enhances the amount of 
probe molecules on the electrode for target capture.  Directed electrochemical nanowire 
assembly (DENA) is an emerging electrodeposition method that produces highly-
textured, 3D nanostructured electrodes14, and has been recently studied in the fabrication 
of various metallic dendritic structures15–19.  Due to the novelty of the technique, most 
studies to date have focused on the fabrication parameters and morphology of the 
resulting dendrites.  However, one group in particular, the Kelley group at the University 
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of Toronto, has significantly contributed to the development of dendritic devices towards 
POC applications. 
 
The Kelley group has fabricated numerous nanostructured microelectrodes (NMEs) for 
the detection of several disease biomarkers20.  Those NMEs were formed from the 
electrodeposition of metal through constricted apertures onto planar gold electrodes13.  
These apertures are within the micron regime, and allow for 3D dendritic structures to 
grow upward off of the planar electrode.  The arrays were functionalized with probe 
molecules and used in the detection of various target analytes, including nucleic 
acids21,22, circulating tumor cells23, and proteins24,25.  NMEs have demonstrated sensitive 
and rapid detection of aM concentrations of nucleic acids26,27 and pM concentrations of 
protein biomarkers28.  While many of these sensors have been used in the detection of 
cancer biomarkers, the Kelley group has recently utilized these arrays in the detection of 
infectious diseases such as HIV28 and rubella29.  Both arrays were comparable to the 
standard ELISA in the detection of these infectious disease biomarkers.  Additionally, 
they incorporated NMEs for detection of rubella virus with a digital microfluidic device, 
allowing for an automated, multiplexed on-chip analysis requiring less than 2 µl of 
sample.  These NMEs have exhibited much potential for further development to POC 
diagnostic devices; currently, the Kelley group is exploring several low-cost substrate 
alternatives to silicon for NMEs, while maintaining reproducibility and high 
electrochemical sensing performance30.     
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We have focused on utilizing 3D pillar arrays as our base substrate for dendritic growth, 
as opposed to the planar substrate used by the Kelley group.  Dendritic growth on pillar 
arrays promotes growth from the pillar tips in a radially upward direction.  We would 
expect to achieve greater surface areas in this manner, whereas planar growth would be 
limited in the vertical direction. While a direct comparison cannot be made to the 
performance of NMEs due to different biomarkers tested, both NMEs and our dendritic 
arrays are comparable in performance to the standard ELISA for the respective 
biomarkers investigated with regard to detection range and LOD.  Additionally, the 
dendritic arrays achieved this level of detection without any biofunctionalization; it is 
expected that conjugation of capture antibody to the dendritic surface would enhance 
sensitivity by eliminating any diffusion limitations.  
 
We have concentrated on 3D pillar arrays as opposed to planar electrodes as our base 
substrate for two reasons.  First, the 3D dendritic arrays outperformed the planar 
dendritic-based sensors in the detection of a CT ELISA.  Second, 3D pillar arrays form 
the base of the ECC arrays.  Therefore, combining the ECC with 3D dendritic growth 
could be doubly advantageous, and overcome the main limitations of each concept.  The 
ECC enables beneficial nanoscale WE-CE proximity, which is lacking in dendritic 
sensors whose WE-CE distance is macroscopic.  3D dendritic structures grown on the 
inner Au core of the ECC would provide an extremely high surface area extending 
outside of the WE-CE annulus, enhancing the limited electrode surface area in standard 
ECCs.  The combination of these two architectures could allow for increased sensitivity 
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and detection through coupling redox cycling capabilities with a high surface-area-to-
volume working electrode. 
 
The DENA process in the macro-scale setup is well-suited for further development 
towards POC applications.  This set-up allows for high scalability as multiple arrays can 
be simultaneously fabricated within minutes; fabricating all arrays on a single chip will 
allow for increased uniformity of dendritic growth, which will allow for reproducible 
electrochemical sensing applications.   Additionally, the one-step fashion of the DENA 
method allows for timely and cost-effective fabrication of arrays, without the need for 
significant training.   
 
To be amenable towards POC applications, future dendritic work will need to focus on 
optimizing and fabricating reproducible dendritic arrays on a single chip.  This will allow 
for biofunctionalization of capture antibody onto the arrays for an on-chip 
electrochemical ELISA, as well as providing a detection platform with multiplexing 
capabilities.  Currently, the photolithographically patterned chips contain only 8 arrays on 
a 16x30 mm2 device.  However, in nanocoaxial studies, arrays as small as 150 µm2 have 
been routinely fabricated.  This array dimension can be applied to the dendritic 
photolithographic chips to incorporate a significantly greater number of individually-
addressed arrays.  These smaller arrays would require much less sample and provide a 
greater number of arrays to multiplex for the detection of numerous biomarkers.  Once 
arrays are reproducibly fabricated and functionalized, microfluidics would need to be 
incorporated to produce a pre-packaged, portable POC diagnostic device. 
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Lab-on-chip devices 
To be fully realized as a POC device, the detection assay must move away from the plate-
based format to a “lab-on-chip” approach in which capture antibody is immobilized 
directly onto the electrode surface. Integration of biomarker capture and electrochemical 
detection on the arrays will allow for a portable and pre-packaged device for POC 
applications.  While biofunctionalization is not a feasible option for the first generation 
nanocoaxial devices due to diffusion issues and inhibited liquid exchange, the extended 
core of the ECC array provides a promising platform that could overcome these 
limitations.  Photolithographically-patterned dendritic arrays constitute an amenable 
platform for antibody functionalization, however studies must first be conducted to obtain 
structurally identical and reproducible dendritic growth on all arrays within the chip.   
 
After further development of the dendritic and nanocoaxial structures, 
biofunctionalization of antibodies can be incorporated onto these plates, allowing for an 
on-chip assay towards POC detection.  We have established several protocols for the 
reproducible conjugation of ELISA antibody onto electrode surfaces using well-studied 
Au-thiol linkage chemistry.  We have demonstrated the use of thiolated protein-G to 
attach antibodies to Au electrode surfaces (e.g. planar, pillar arrays) without insulating 
the electrode surface, allowing for the nanosensor to transduce electrochemical signal 
despite the protein layer on the conducting electrode.  Additionally, using protein-G 
conjugation allows the ELISA to be adjusted for any target protein biomarker, as any IgG 
antibody will bind to protein-G; this is advantageous in producing multiplexed on-chip 
ELISAs to screen for multiple disease biomarkers.  While our ELISA still relies on an 
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enzymatic label for biomarker detection, a label-free reporter antibody could be 
developed using quantum dots or gold nanoparticles loaded with a redox reporter 
molecule.   
 
Biofunctionalization arrays must be coupled with some type of microfluidic device in 
order to produce a stable and portable POC device that contains required buffer and 
reagent.  Microfluidic packaging allows for portability but also ease of use for untrained 
personnel in resource limited areas.  Microfluidic paper-based analytical devices 
(µPADs) are a newer class of microfluidics that is being designed specifically with 
developing countries in mind.  µPADs combine the capabilities of conventional 
microfluidics while maintaining the simplicity of diagnostic test strips31; they require no 
external supporting equipment and are controlled largely by capillary motion, making 
them inexpensive and easy to use.  One well-known application of µPADs is their use for 
glucose monitoring in diabetic patients32.  
 
Nanocoaxial and dendritic arrays could be incorporated into µPADs for POC devices.  
Papers containing conducting carbon or metal fibers are electrically conducting and could 
be used to create an electrochemical µPAD composed of dendritic or nanocoaxial 
structures.  Electrochemical µPADs have been successfully demonstrated by Dunchai et 
al.33 for the detection of glucose, lactate, and uric acid, providing proof-of-concept for 
such devices.  Electrochemical nanostructured µPADs could allow for sensitive and 
quantitative readout of target biomarkers when used in conjunction with a held-hand 
potentiostat and a smartphone or tablet.  Hand-held potentiostats would allow for a 
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portable method to quantitate electrochemical reactions on the µPAD, and could 
transduce this information via USB to visualizing software installed on a 
smartphone/tablet.  An example of a potential POC device is shown below in Figure 5.1.   
 
Figure 5.1. POC nanodevice.  (a) Test strip based on nanocoax or dendritic architecture 
(not to scale). (b) Adaptor box in which to insert test strip for readout on the (c) hand-
held potentiostat.  (d) Hand held potentiostats have bluetooth and USB ports for direct 
readout on a smart phone, tablet, or computer. 
 
Future scope 
To test the true POC capabilities of such a device, it would need to undergo shelf-life 
stability testing and field testing.  Studies would be conducted on the stability of the 
reagents in the chip and its performance after weeks to months of shelf-life.  
Additionally, devices would be placed in extreme temperatures, especially heat, over a 
certain amount of time to mimic the environment of many resource-limited areas in need 
of POC diagnostics.  Specificity and sensitivity profiles of the device would need to be 
obtained from blind sample testing in order to assess the percentage of false positives and 
false negatives.     
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Potential pitfalls in such a device include biofouling and reagent stability.  Biofouling is a 
common issue with electrochemical devices, as the high level of proteins in serum and 
heterogeneous samples are prone to non-specifically stick to metal electrodes.  However, 
blocking protocols and/or pre-dilution of the sample are robust methods to overcome 
biofouling.  Pre-dilution can even be incorporated into the microfluidic design, 
automating the process on-chip.  Issues with reagent stability in harsh conditions may be 
encountered.  One efficient technique to avoid reagent degradation is to store the reagents 
in a lyophilized state on the device.  Both issues are well-documented and these solutions 
have been used successfully to circumvent these problems.     
 
With further development and incorporation into a lab-on-chip microfluidic system, our 
nanoarchitectures could facilitate much-needed quantitative analysis of disease 
biomarkers in resource-limited areas as opposed to currently available “yes/no” type 
options.  Quantitative analysis would allow for proper monitoring of disease, preventing 
epidemic outbreaks and providing better care for the patient.  Additionally, these 
multiplexed devices could test for multiple diseases simultaneously.  This is extremely 
beneficial since many diseases exhibit similar symptoms; therefore, a panel of biomarkers 
could be screened from one sample, providing better patient diagnosis and thus 
prognosis.  Finally, and possibly most importantly, the fabrication techniques used would 
allow for an economical and cost-effective device, a must-have characteristic in POC 
diagnostics. 
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Introduction 
Molecular imprinting is a technique that creates tailor-made binding sites to a specific 
antigen or molecule based on memory of size, shape, and functional group charge of that 
template molecule1.  Imprints are formed when the template molecule of choice is mixed 
with a functional monomer and an excess of cross-linking agent; this solution 
polymerizes and coats the electrode surface in the presence of current.  The template 
molecule can then be extracted, leaving behind specific recognition sites complementary 
in shape, size, and chemical functionality (e.g. hydrogen bonds, dipole-dipole, ionic 
interactions) to the template.  
Often known as “artificial antibodies”, molecular imprints possess high affinity and 
selectivity for their target template.  Compared to biological probes such as antibodies 
and nucleic acids, imprints exhibit a higher physical robustness and resistance towards 
elevated temperatures2.  Additionally, they are less expensive to synthesize and can be 
maintained at room temperature for years while maintaining their recognition capacities.  
While all of these factors place molecular imprint technology at a high advantage over 
conventional antibody detection in biosensing, one major obstacle remains in the way.  
Molecular imprinting has been most successful in the detection of small molecules and in 
mostly non-aqueous media.  The application of molecular imprinting towards large 
molecule, protein detection in aqueous-based solutions has remained somewhat of a 
challenge; proteins possess high surface complexity, conformational flexibility, and large 
sizes not encountered in polymer materials typically used in imprinting3. 
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We have developed molecular imprint (MIP) devices for the detection of ferritin and 
human papillomavirus derived E7 protein on carbon-nanotube tips coated in phenol 
polymer4.  Using the same polymer and imprinting technique, we are moving toward a 
simpler platform of planar gold.  Carbon nanotubes are expensive and timely to fabricate; 
planar gold electrodes would allow for a simple substrate on which to fabricate sensitive 
MIP devices that would provide high yield and lower cost.  Previously, planar gold MIP 
devices were fabricated and characterized using streptavidin as the template protein5.  
Here, we examine preliminary studies on planar gold MIP devices using cholera toxin 
(CT) as the template protein.    
Materials and Methods 
Planar Au substrates were prepared with wells as previously described.  
Electropolymerization was performed on a Reference 600 potentiostat or on a Reference 
1000 potentiostat (Gamry Instruments, Warminster, PA) using a three-electrode system.  
An external Ag/AgCl wire served as the reference electrode and an external Pt wire 
served as the counter electrode.   The Au substrate to be electropolymerized functioned as 
the working electrode.  Immediately before electropolymerization, substrates were 
cleaned with UV/ozone for 20 min. 
Molecular imprinted polymers (MIPs) were formed via electropolymerization of phenol 
onto Au substrates via cyclic voltammetry (CV).  Solution containing 100 µg/ml of 
template protein and 2.5 mM phenol in PBS, pH 7.4, were pipetted onto the substrate.  
Using single frequency electrochemical impedance spectroscopy (SEIS), a 300 mV DC 
voltage was applied for 30 s to attract the template protein to the Au surface.  CV was 
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then immediately carried out to electropolymerize the protein/polyphenol film.  CVs were 
performed with a scan rate of 50 mV/s and a step size of 2 mV for 5 cycles, sweeping 
between 0 V to 0.9 V.  Electropolymerization was confirmed by square wave 
voltammetry (SWV) measurements with 1 mM FCA in PBS, pH 7.4 with the potential 
range of 0 V to 0.5 V, a pulse size of 50 mV, and a frequency of 10 Hz. 
To remove the template protein and form the resulting MIP, the substrate was incubated 
with 100 µg/ml proteinase K in 1% SDS/0.1% AcOH overnight at room temperature and 
then rinsed 3 times with PBS, pH 7.4.  Non-imprinted polymers (NIPs) were formed in 
the exact same manner, except no template protein was incorporated into the phenol 
solution during electropolymerization.     
Re-binding of template protein was performed in PBS, 7.4 with an incubation time of 20 
min.  The solution was gently pipetted out and no rinses were performed.  SWV was 
performed to analyze binding using 1 mM FCA, PBS 7.4 with the same parameters as 
described above.      
Results 
Previously, differential pulse voltammetry (DPV) was the method used for 
electrochemical measurement in MIP studies.  In the following studies, square wave 
voltammetry (SWV) was the chosen method over DPV.  This was due to the presence of 
a flatter baseline during measurements with SWV over DPV, resulting in more defined, 
sharper peak currents (Figure A.1).  In Figure A.1.a., DPV was used to measure 1 mM 
FCA in PBS, pH 7.4 on a planar gold MIP device after extraction of template protein (in 
this case, streptavidin).  Here, the baseline current drifts in a significant upward sloping 
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fashion, making it harder to elucidate the true peak current.  The baseline begins ar 
approximately 1 µA and rises to about 5 µA over the measurement period.  In Figure 
A.1.b., SWV was used to measure 1 mM FCA on a planar gold MIP after streptavidin 
extraction as well.  With the SWV method, the baseline remains noticeably flatter and 
demonstrates a much smaller upward slope, making the peak current much sharper and 
not hidden underneath the baseline as with the DPV method.  Additionally, the baseline 
current with SWV increases by less than 1 µA over the entire measurement period.  
Therefore, SWV was used for the rest of the MIP studies as the method of 
electrochemical detection.      
Preparation of the planar gold sample prior to electropolymerization was also examined.  
Two planar gold samples were either UV/ozone cleaned for 20 min, while two other 
planar gold samples were only cleaned with ethanol (did not undergo UV/ozone 
treatment). One sample from each cleaning group was electropolymerized with template 
molecule (CT) to form two MIP samples, whereas the other sample from each group was 
electropolymerized without CT to form the two NIP control samples.  All four samples 
underwent extraction overnight (100 µg/ml proteinase K in 1% SDS/0.1% AcOH) and 
were rinsed in the morning with PBS.  SWV signals of 1 mM FCA on all four resulting 
samples are shown Figure A.2.  In Figure A.2.a, SWV signals are shown for the MIP 
(black) and NIP (red) samples whose planar gold substrate had undergone UV/ozone 
cleaning prior to electropolymerization.  The NIP sample remains undamaged and intact 
on the planar gold, indicated by the significantly flat baseline in the SWV signal at the 
oxidation potential of FCA.  The lack of peak current indicates that the electrically 
insulating polymer layer is in intact and preventing redox reaction at the gold surface.  
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Significant damage to NIP samples is typically designated by peak currents > 500 nA.  
The MIP sample demonstrates proper and good extraction of the template protein CT, 
indicated in the SWV by the well-defined, µA regime peak.  The peak current, 
determined by subtracting the current to baseline at 0.05 V, was approximately 2 µA.  
Good MIP samples typically demonstrate peak currents of 1 – 3 µA. 
The SWV signals for the MIP (black) and NIP (red) samples that did not undergo 
UV/ozone cleaning are shown in Figure A.2.b.  Here, the NIP sample also remains 
undamaged and intact, indicated by the significantly flat baseline in the SWV signal at 
the oxidation potential of FCA.  The MIP sample, on the other hand, demonstrated less 
extraction compared to the UV/ozone cleaned sample in Fig. A.2.a.  The peak current in 
this MIP was approximately 0.5 µA, as determined by subtracting the current to baseline 
at 0.05 V.  Therefore, all future planar gold samples were UV/ozone cleaned prior to 
electropolymerization.   
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Figure A.1.  Current response to the oxidation of 1 mM FCA on a molecularly imprinted 
polymer (MIP) after template protein (streptavidin) had been extracted.  (a) DPV. (b) 
SWV. X-axis: potential (V); y-axis: current (I). 
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Figure A.2. SWVs of 1 mM FCA on samples with varying preparation technique.  MIP 
samples were electrochemically examined with FCA after template protein streptavidin 
had been extracted (black).  Control NIPs were electrochemically examined as well 
(shown in red) after exposure to identical extraction conditions.  (a) SWVs of MIP and 
NIP samples that had undergone UV/ozone clean immediately prior to 
electropolymerization.  (b) SWVs of MIP and NIP samples that did not undergo 
UV/ozone cleaning before electropolymerization.  
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Typical template protein concentrations in previous studies with ferritin and streptavidin 
had been 100 µg/ml.  We examined this template concentration in CT MIPs, as well as 1 
µg/ml due to the fact that the CT beta subunit used was smaller than the previous proteins 
examined.  Two CT MIPs were fabricated using either 100 µg/ml CT or 1 µg/ml CT as 
the template concentration.  A NIP control was also fabricated with no template protein.  
All three samples underwent extraction overnight, and then underwent rebinding with CT 
in PBS, pH 7.4.  CT concentrations ranging from 1 fg/ml to 10 µg/ml were serially 
incubated on the samples for 20 min each and SWVs were performed with 1 mM FCA.  
The resulting SWV signals are shown in Figure A.3.  All SWV signals were subtracted to 
the third data point to determine the peak current. 
Range of detection for the two CT MIPs with varying template concentrations is shown 
in Figure A.4.  Peak current (Ip) is plotted against the CT concentration (from rebinding) 
for the 1 µg/ml template CT MIP (black), 100 µg/ml template CT MIP (red), and the NIP 
control (blue).  The 1 µg/ml template CT MIP does not exhibit a significant 
concentration-dependent response, indicated by the large error bars (determined by 
standard deviation).  The 100 µg/ml template CT MIP demonstrated a concentration-
dependent response, and exhibited tighter error bars overall.  Therefore, the 100 µg/ml 
template concentration will be maintained for CT MIP studies.    
Four CT MIP samples were fabricated on planar gold to examine CT rebinding as well as 
non-specific binding of other proteins of similar size (interleukin-2; IL2) and shape (shiga 
toxin; Stx).  Each of the four CT MIPs were incubated with one of the above proteins 
over a serial range of 10-6 to 103 ng/ml in PBS, pH 7.4 for 20 min at each concentration.  
After each 20 min incubation, SWVs were taken in 1 mM FCA.  The peak currents (Ip) 
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determined from the SWVs are plotted in Figure A.5 against concentration of each 
protein.  The two CT MIP samples (MIP-1, MIP-2) plotted in black underwent rebinding 
with CT.  The two samples varied in their current magnitude; MIP-2 (dashed black) 
began with a higher starting peak current of about 4.2 µA whereas MIP-1 (solid black) 
began with a starting peak current of about 2 µA.  This demonstrates variability in the 
extraction and/or polymerization process that needs to be assessed to fabricate 
reproducible devices.  Both of these MIP samples, despite their different in current 
magnitudes, appear to demonstrate a concentration-dependent response; as CT 
concentration increases, current peak decreases.  However, the two other MIPs with 
which IL2 (red) and Stx (blue) were incubated exhibit the same concentration-dependent 
response; they are even on the same current magnitude scale and slope grade as the CT 
rebinding on MIP-1 sample.  The NIP control sample (magenta) does not exhibit the 
same current magnitude and has a lower background comparatively, but the same trend 
can be seen at the smaller current magnitude; the current is decreasing with the NIP 
sample as more CT is added. Therefore, this dose-dependent response is not specific to 
the imprint, but suggests non-specific binding of proteins to the polymer surface.  
However, the presence of imprints aggravates this effect as the imprints may provide 
more surface area for which the proteins can stick and cause more of an insulating change 
in the electrochemical response.   
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Figure A.3. SWVs of CT rebinding on MIPs of varying CT template concentration. 
SWVs of CT rebinding on MIPs of varying CT template concentration. (a) CT MIP 
produced using CT template concentration of 100 µg/ml. (b) CT MIP produced from 1 
µg/ml CT template concentration. (c) NIP control; no CT template used, polymer only.  
All SWVs were subtracted to baseline at the third data point to determine peak currents. 
X-axis: potential (V); y-axis: current (I). 
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Figure A.4. Detection range of CT rebinding on MIPs of varying template concentration.  
On the y-axis, peak current (Ip) is plotted against CT concentration on the x-axis.  Peak 
current was determined from the baselined SWV signals from Figure A.3.  Rebinding of 
CT on a CT MIP produced with 100 µg/ml template CT is shown in red.  Rebinding of 
CT on a CT MIP fabricated with 1 µg/ml template CT is shown in black.  The NIP 
control is shown in blue; the same CT concentrations are exposed to the NIP in order to 
assess non-specific binding.  Both CT MIPs represent two trials on the same device 
whereas the NIP data represents on trial.  Error bar shown is standard deviation.     
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Figure A.5. Rebinding of proteins on CT MIP devices.  Four CT MIP devices were 
fabricated (CT MIP-1, -2, -3, -4) as well as a NIP control.  Protein samples of varying 
concentrations were added to each device and the current was recorded.  On the y-axis, 
the peak current is plotted against the protein concentration added.  CT was rebound on 
two of the MIP devices: CT MIP-1 (black; solid line) and CT MIP-2 (black; dashed line).  
IL2 was added to CT MIP-3 (red) and Stx was added to CT MIP-4 (blue) to examine 
non-specific binding of non-template protein on the imprint.  CT was additionally added 
to the NIP control sample (magenta) to examine non-specific binding of protein on 
polymer without imprints.  Each data set represents two trials.  Error bar shown is 
standard deviation.  X-axis: concentration (ng/ml); y-axis: peak current (Ip).      
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